Nothing Special   »   [go: up one dir, main page]

WO2009095479A2 - Prodrug comprising a self-cleavable linker - Google Patents

Prodrug comprising a self-cleavable linker Download PDF

Info

Publication number
WO2009095479A2
WO2009095479A2 PCT/EP2009/051079 EP2009051079W WO2009095479A2 WO 2009095479 A2 WO2009095479 A2 WO 2009095479A2 EP 2009051079 W EP2009051079 W EP 2009051079W WO 2009095479 A2 WO2009095479 A2 WO 2009095479A2
Authority
WO
WIPO (PCT)
Prior art keywords
prodrug
group
mmol
poly
alkyl
Prior art date
Application number
PCT/EP2009/051079
Other languages
French (fr)
Other versions
WO2009095479A3 (en
Inventor
Felix Cleemann
Ulrich Hersel
Silvia Kaden
Harald Rau
Thomas Wegge
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RS20190789A priority Critical patent/RS58948B1/en
Priority to LTEP09706788.8T priority patent/LT2237799T/en
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Priority to DK09706788.8T priority patent/DK2237799T3/en
Priority to ES09706788T priority patent/ES2733355T3/en
Priority to PL09706788T priority patent/PL2237799T3/en
Priority to AU2009209565A priority patent/AU2009209565B2/en
Priority to EP21202920.1A priority patent/EP3981761A3/en
Priority to SI200931976T priority patent/SI2237799T1/en
Priority to BRPI0906643A priority patent/BRPI0906643A2/en
Priority to US12/865,693 priority patent/US8906847B2/en
Priority to CN2009801110881A priority patent/CN101980725B/en
Priority to CA2712224A priority patent/CA2712224C/en
Priority to EP09706788.8A priority patent/EP2237799B1/en
Priority to MX2010008024A priority patent/MX2010008024A/en
Priority to JP2010544717A priority patent/JP5588354B2/en
Priority to EP13156350.4A priority patent/EP2596805B1/en
Publication of WO2009095479A2 publication Critical patent/WO2009095479A2/en
Publication of WO2009095479A3 publication Critical patent/WO2009095479A3/en
Priority to IL207150A priority patent/IL207150A/en
Priority to ZA2010/05413A priority patent/ZA201005413B/en
Priority to HK11106352.6A priority patent/HK1152240A1/en
Priority to US14/528,362 priority patent/US20150057221A1/en
Priority to US15/385,179 priority patent/US20170100490A1/en
Priority to HRP20191052 priority patent/HRP20191052T1/en
Priority to CY20191100707T priority patent/CY1121961T1/en
Priority to US16/654,667 priority patent/US20200046725A1/en
Priority to US17/847,750 priority patent/US20220331334A1/en
Priority to US18/479,445 priority patent/US20240041897A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom

Definitions

  • Prodrug comprising a drug linker conjugate
  • the present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L.
  • the invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
  • Such drug can be conjugated with a carrier.
  • carriers in drug delivery are either used in a non-covalent fashion, with the drug physicochemically formulated into a solvent-carrier mixture, or by covalent attachment of a carrier reagent to one of the drug's functional groups.
  • the drugs may be conjugated to a carrier through covalent bonds.
  • This approach is applied to various classes of molecules, from so-called small molecules, through natural products up to larger proteins.
  • Covalent drug carrier conjugates can be divided into two groups. Firstly, conjugates, where the covalent bond between carrier and drug is mostly present during the action of the drug ("permanent covalent bond"), i.e. a derivative of the drug exhibits its pharmacological effects as it is known for the drug as such. Secondly, the covalent bond is mostly previously cleaved to release the drug as such, which can exhibit its known pharmacological effects. In the latter case the covalent drug carrier conjugate is called carrier linked prodrug or carrier prodrug. In order to ensure cleavage of the covalent bond between carrier and drug easy removal of said bond in vivo is required to release the drug (prodrug activation).
  • Prodrug activation may occur by enzymatic or non-enzymatic cleavage of the bond between the carrier and the drug molecule, or a sequential combination of both, i.e. an enzymatic step followed by a non-enzymatic rearrangement.
  • Enzymatically induced prodrug activation is characterized in that the cleavage in enzyme-free in-vitro environment such as an aqueous buffer solution, of, e.g., an ester or amide may occur, but the corresponding rate of hydrolysis may be much too slow and not therapeutically useful.
  • enzyme-free in-vitro environment such as an aqueous buffer solution
  • esterases or amidases are typically present and the esterases and amidases may cause significant catalytic acceleration of the kinetics of hydrolysis from twofold up to several orders of magnitude. Therefore, the cleavage is predominantly controlled by the enzymatic reaction.
  • Enzyme levels may differ significantly between individuals resulting in biological variation of prodrug activation by the enzymatic cleavage.
  • the enzyme levels may also vary depending on the site of administration. For instance it is known that in the case of subcutaneous injection, certain areas of the body yield more predictable therapeutic effects than others. To reduce this unpredictable effect, non-enzymatic cleavage or intramolecular catalysis is of particular interest.
  • enzyme-independent autocatalytic cleavage of carrier and biologically active moiety is preferred. In most cases this is achieved by an appropriately designed linker moiety between the carrier and the biologically active moiety, which is directly attached to the functional group of a biologically active moiety via covalent bond.
  • ester based prodrugs where the carrier is water-soluble and the biologically active moiety is derived from HIV-I protease inhibitor KNI-727.
  • the linker used is attached to the biologically active moiety via ester group.
  • the mechanism of this prodrug system is cyclization-activation by cyclic imide formation for the cleavage of ester bonds.
  • ester groups may be less chemoselectively addressable for the conjugation of the carrier or linker and the drug.
  • prodrug system based on N,N-bis-(2-hydroxyethyl)glycine amide (bicine) linker is described.
  • two PEG carrier molecules are linked to a bicine molecule coupled to an amino group of the drug molecule.
  • the first two steps in prodrug activation is the enzymatic cleavage of the first linkages connecting both PEG carrier molecules with the hydroxy groups of the bicine activating group.
  • Different linkages between PEG and bicine are described resulting in different prodrug activation kinetics.
  • the second step in prodrug activation is the cleavage of the second linkage connecting the bicine activating group to the amino group of the drug molecule.
  • an object of the present invention is to provide such drug linker conjugates, where the linker is covalently attached via a cleavable bond to a biologically active moiety (representing the drug after release), and where the linker is further covalently attached via a permanent bond to a carrier directly or via a spacer to form the carrier- linked prodrug.
  • -D is a nitrogen containing biologically active moiety
  • -L is a non-bio logically active linker moiety -L 1 represented by formula (I),
  • X is C(R 4 R 4a ); N(R 4 ); O; C(R 4 R 4a )-C(R 5 R 5a ); C(R 5 R 5a )-C(R 4 R 4a ); C(R 4 R 4a )-N(R 6 ); N(R 6 )- C(R 4 R 4a ); C(R 4 R 4a )-O; or O-C(R 4 R 4a );
  • X I is C; or S(O);
  • X 2 is C(R 7 , R 7a ); or C(R 7 , R 7a )-C(R 8 , R 8a );
  • X 3 is O; S; or N-CN;
  • R 1 , R la , R 2 , R 2a , R 3 , R 3a , R 4 , R 4a , R 5 , R 5a , R 6 , R 7 , R 7a , R 8 , R 8a are independently selected from the group consisting of H; and Ci_ 4 alkyl;
  • one or more of the pairs R la /R 4a , R la /R 5a , R 4a /R 5a , R 7a /R 8a form a chemical bond;
  • one or more of the pairs RVR la , R 2 /R 2a , R 4 /R 4a , R 5 /R 5a , R 7 /R 7a , R 8 /R 8a are joined together with the atom to which they are attached to form a C 3 _ 7 cycloalkyl; or 4 to 7 membered heterocyclyl;
  • R 4 /R 6 are joined together with the atoms to which they are attached to form a saturated 4 to 7 membered heterocyclyl;
  • one or more of the pairs RVR 4 , RVR 5 , RVR 6 , R 4 /R 5 , R 4 /R 6 , R 7 /R 8 , R 2 /R 3 are joined together with the atoms to which they are attached to form a ring A;
  • R 3 /R 3a are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle;
  • A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C 3-10 cycloalkyl; 4 to 7 membered heterocyclyl; and 9 to 11 membered heterobicyclyl; and
  • L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent;
  • L 2 is a single chemical bond or a spacer; and Z is a carrier group.
  • Examples for such preferred cyclic cleavage products are substituted succinimide or glutarimide ring structures.
  • Prerequisite for such cyclization activation is the presence of an amine-containing nucleophile in the linker structure and another amide bond which is not the amide prodrug bond but an amide bond substituted with a hydrogen atom.
  • the amine-containing nucleophile serves as a neighbouring group to enhance the nucleophilicity of the nitrogen contained in the permanent amide bond which in turn attacks the prodrug amide carbonyl group and consequently induces intramolecular acylation of the permanent amide bond generating the cyclic imide ring.
  • linker structures comprise a permanent linkage to a carrier, an amine- containing nucleophile, and a permanent amide bond with a hydrogen attached to the nitrogen of the amide bond.
  • Corresponding carrier- linked prodrugs comprise a linker containing a permanent linkage to a carrier, an amine-containing nucleophile and said permanent amide bond, and a nitrogen containing biologically active moiety derived from the drug conjugated to the linker by means of a cleavable amide bond.
  • Fig. 1 shows an example of the cleavage resulting in a cyclic imide.
  • the nitrogen of the biologically active moiety is shown as hydrogen containing amine, which results in a drug having a primary amine functional group.
  • a secondary amine may be part of the drug.
  • the one to four mandatory substituents L 2 -Z including the carrier are not shown.
  • Preferred properties of the prodrug are given by a half- life of hydrolysis in aqueous buffer at pH 7.4 and 37°C between 1 h and 3 months; similar rates of hydrolysis under physiological conditions in buffer and plasma.
  • the prodrug according to the present invention may show excellent in vivo/in vitro correlation of linker cleavage, a high degree of enzyme independence and can be stored at lower pH (pH dependent cleavage).
  • Bioly active moiety D means the part of the drug linker conjugate, which results after cleavage in a drug D-H of known biological activity.
  • Non-active linker means a linker which does not show the pharmacological effects of the drug derived from the biologically active agent.
  • Alkyl means a straight-chain or branched carbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent.
  • Ci_ 4 alkyl means an alkyl chain having 1 - 4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl tert-butyl, or e.g. - CH 2 -, -CH 2 -CH 2 -, -CH(CH 3 )-, -CH 2 -CH 2 -CH 2 -, -CH(C 2 H 5 )-, -C(CH 3 ) 2 -, when two moieties of a molecule are linked by the alkyl group.
  • Each hydrogen of a Ci_4 alkyl carbon may be replaced by a substituent.
  • Ci_6 alkyl means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: Ci_ 4 alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl; tert-butyl, n-pentyl, n-hexyl, or e.g.
  • Ci_6 alkyl carbon when two moieties of a molecule are linked by the alkyl group.
  • Each hydrogen of a Ci_6 alkyl carbon may be replaced by a substituent.
  • C 1-18 alkyl means an alkyl chain having 1 to 18 carbon atoms and "C 8-18 alkyl” means an alkyl chain having 8 to 18 carbon atoms. Accordingly, “Ci_ 5 o alkyl” means an alkyl chain having 1 to 50 carbon atoms.
  • Each hydrogen of a C 2 _ 5 o alkenyl carbon may be replaced by a substituent as further specified. Accordingly, the term "alkenyl” relates to a carbon chain with at least one carbon carbon double bond. Optionally, one or more triple bonds may occur.
  • C 2 _ 5 o alkynyl means a branched or unbranched alkynyl chain having 2 to 50 carbon atoms, e.g. if present at the end of a molecule: -C ⁇ CH, -CH 2 -C ⁇ CH, CH 2 -CH 2 -C ⁇ CH, CH 2 -C ⁇ C- CH 3 , or e.g. -C ⁇ C- when two moieties of a molecule are linked by the alkynyl group.
  • Each hydrogen of a C2-50 alkynyl carbon may be replaced by a substituent as further specified.
  • alkynyl relates to a carbon chaim with at lest one carbon carbon triple bond. Optionally, one or more double bonds may occur.
  • C 3 _ 7 cycloalkyl or “C 3 _ 7 cycloalkyl ring” means a cyclic alkyl chain having 3 to 7 carbon atoms, which may have carbon-carbon double bonds being at least partially saturated, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent.
  • the term “C 3 _ 7 cycloalkyl” or “C 3 _ 7 cycloalkyl ring” also includes bridged bicycles like norbonane or norbonene. Accordingly, "C 3 _ 5 cycloalkyl” means a cycloalkyl having 3 to 5 carbon atoms.
  • C3_io cycloalkyl means a cyclic alkyl having 3 to 10 carbon atoms, e.g. C3_7 cycloalkyl; cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl.
  • C 3-10 cycloalkyl also includes at least partially saturated carbomono- and -bicycles.
  • Halogen means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
  • Examples for a 4 to 7 membered heterocycles are azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydro furan, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyr
  • Examples for a 9 to 11 membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine.
  • 9 to 11 membered heterobicycle also includes spiro structures of two rings like l,4-dioxa-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.
  • the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
  • the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
  • Compounds of the formula (I) which contain one or more basic groups i.e.
  • acids which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
  • suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art.
  • the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
  • the respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
  • the present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
  • pharmaceutically acceptable means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.
  • “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable excipient (pharmaceutically acceptable carrier).
  • excipient refers to a diluent, adjuvant, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical excipient can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • Water is a preferred excipient when the pharmaceutical composition is administered orally.
  • Saline and aqueous dextrose are preferred excipients when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid excipients for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and excipients such as triglycerides.
  • Oral formulation can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical excipients are described in "Remington's Pharmaceutical Sciences” by E.W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of excipient so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
  • X 3 is O.
  • X is N(R 4 ), X 1 is C and X 3 is O.
  • X 2 is C(R 7 R 7a ).
  • L 1 is selected from the group consisting of
  • R is H; or Ci -4 alkyl
  • Y is NH; O; or S
  • R 1 , R la , R 2 , R 2a , R 3 , R 3a , R 4 , X, X 1 , X 2 have the meaning as indicated above.
  • L 1 is selected from the group consisting of
  • At least one (up to four) hydrogen is replaced by a group L 2 -Z.
  • each L 2 and each Z can be selected independently.
  • L 2 can be attached to L 1 at any position apart from the replacement of the hydrogen marked with an asterisk in formula (I).
  • one to four of the hydrogen given by R, R 1 to R 8 directly or as hydrogen of the Ci_ 4 alkyl or further groups and rings given by the definition of R and R 1 to R 8 are replaced by L 2 -Z.
  • L 1 may be optionally further substituted.
  • any substituent may be used as far as the cleavage principle is not affected.
  • one or more further optional substituents are independently selected from the group consisting of halogen; CN; COOR 9 ; OR 9 ; C(O)R 9 ; C(O)N(R 9 R 9a ); S(O) 2 N(R 9 R 9a ); S(O)N(R 9 R 9a ); S(O) 2 R 9 ; S(O)R 9 ; N(R 9 )S(O) 2 N(R 9a R 9b ); SR 9 ; N(R 9 R 9a ); NO 2 ; OC(O)R 9 ; N(R 9 )C(O)R 9a ; N(R 9 )S(O) 2 R 9a ; N(R 9 )S(O)R 9a ; N(R 9 )C(O)OR 9a ; N(R 9 )C(O)N(R 9a R 9b ); OC(O)N(R 9 R 9a ); T; Ci -50 alkyl; C
  • T is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C 3-10 cycloalkyl; 4 to 7 membered heterocyclyl; or 9 to 11 membered heterobicyclyl, wherein T is optionally substituted with one or more R 10 , which are the same or different;
  • R 11 , R l la , R 12 , R 12a , R 12b are independently selected from the group consisting of H; or Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
  • interrupted means that between two carbons a group is inserted or at the end of the carbon chain between the carbon and hydrogen.
  • L 2 is a single chemical bond or a spacer.
  • L 2 is a spacer, it is preferably defined as the one or more optional substituents defined above, provided that L 2 is substituted with Z.
  • L 2 -Z is COOR 9 ; OR 9 ; C(O)R 9 ; ( ); ( ) ; ( ) ( ) ; ( ) ( ) 2 ; ( ) ( ) ( ) ; ( ) ( ) ; alkenyl; or C 2 - 50 alkynyl, wherein T; Ci_5o alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R 10 , which are the same or different and wherein Ci .50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -
  • R 9 , R 9a , R 9b are independently selected from the group consisting of H; Z; T; and Ci_so alkyl; C 2 _5o alkenyl; or C 2 _so alkynyl, wherein T; Ci_so alkyl; C 2 _so alkenyl; and C 2 _so alkynyl are optionally substituted with one or more R 10 , which are the same or different and wherein Ci_so alkyl; C 2 _so alkenyl; and C 2 _so alkynyl are optionally interrupted by one or more groups selected from the group consisting of ( ) ( ) ( ) ( 11 ) ( ) ( 11 ) - ;
  • T is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C 3-10 cycloalkyl; 4 to 7 membered heterocyclyl; or 9 to 11 membered heterobicyclyl, wherein t is optionally substituted with one or more R 10 , which are the same or different;
  • alkyl is optionally substituted with one or more halogen, which are the same or different;
  • R 11 , R l la , R 12 , R 12a , R 12b are independently selected from the group consisting of H; Z; or Ci_ 6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • R 9 , R 9a , R 9b , R 10 , R 11 , R l la , R 12 , R 12a , R 12b is Z.
  • L 2 is a Ci_ 2 o alkyl chain, which is optionally interrupted by one or more groups independently selected from -0-; and C(0)N(R 3aa ); optionally substituted with one or more groups independently selected from OH; and C(O)N(R 3aa R 3aa ); and wherein R 3aa , R 3aaa are independently selected from the group consisting of H; and Ci_4 alkyl.
  • L 2 has a molecular weight in the range of from 14 g/mol to 750 g/mol.
  • L 2 is attached to Z via a terminal group selected from
  • L 2 has such terminal group it is furthermore preferred that L 2 has a molecular weight in the range of from 14 g/mol to 500 g/mol calculated without such terminal group.
  • L is represented by formula (Ia)
  • R 4 , L 2 , and Z have the meaning as indicated above, and wherein R 3aa , R 3aaa are independently selected from the group consisting of H; and Ci_4 alkyl; or are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle.
  • R 4 is H; or methyl.
  • L is represented by formula (Ib)
  • R 1 , R la , R 4 , L 2 and Z have the meaning as indicated above, and wherein R 3aa is H; or Ci_4 alkyl.
  • R 4 is H; or methyl.
  • R 1 in formula (I) is L 2 -Z.
  • R 3 in formula (I) is L 2 -Z.
  • R 3 , R 3a in formula (I) are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle, wherein the heterocycle is substituted with i ⁇ z.
  • D-H is a small molecule bioactive agent or a biopolymer.
  • D-H is a biopolymer selected from the group of biopolymers consisting of proteins, polypeptides, oligonucleotides, and peptide nucleic acids.
  • Oligonucleotides means either DNA, RNA, single-stranded or double-stranded, siRNA, miRNA, aptamers, and any chemical modifications thereof with preferably 2 to 1000 nucleotides. Modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole.
  • Such modifications include, but are not limited to, 2'-position sugar modifications, 5- position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5 -io do -uracil; backbone modifications, methylations, unusual base- pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping and change of stereochemistry.
  • D-H is a polypeptide selected from the group of polypeptides consisting of ACTH, adenosine deaminase, agalsidase, alfa-1 antitrypsin (AAT), alfa-1 proteinase inhibitor (API), alteplase, amylins (amylin, symlin), anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal, and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, atosiban, biphalin, bivalirudin, bone-morphogenic proteins, bovine pancreatic trypsin inhibitor (BPTI), cadherin fragments, calcitonin (salmon), collagenase, complement Cl esterase inhibitor, conotoxins, cytokine receptor fragments, DNase, dynorphine A, endorphins,
  • ACTH
  • D-H is a protein prepared by recombinant DNA technologies.
  • D-H is a protein selected from the group of proteins consisting of antibody fragments, single chain antigen binding proteins, catalytic antibodies and fusion proteins.
  • D-H is a small molecule bioactive agent selected from the group of agents consisting of central nervous system-active agents, anti-infective, anti-allergic, immunomodulating, anti-obesity, anticoagulants, antidiabetic, anti-neoplastic, antibacterial, anti-fungal, analgesic, contraceptive, anti-inflammatory, steroidal, vasodilating, vasoconstricting, and cardiovascular agents with at least one primary or secondary amino group.
  • agents consisting of central nervous system-active agents, anti-infective, anti-allergic, immunomodulating, anti-obesity, anticoagulants, antidiabetic, anti-neoplastic, antibacterial, anti-fungal, analgesic, contraceptive, anti-inflammatory, steroidal, vasodilating, vasoconstricting, and cardiovascular agents with at least one primary or secondary amino group.
  • D-H is a small molecule bioactive agent selected from the group of agents consisting of acarbose, alaproclate, alendronate, amantadine, amikacin, amineptine, aminoglutethimide, amisulpride, amlodipine, amotosalen, amoxapine, amoxicillin, amphetamine, amphotericin B, ampicillin, amprenavir, amrinone, anileridine, apraclonidine, apramycin, articaine, atenolol, atomoxetine, avizafone, baclofen, benazepril, benserazide, benzocaine, betaxolol, bleomycin, bromfenac, brofaromine, carvedilol, cathine, cathinone, carbutamid, cefalexine, clinafloxacin, ciprofloxacin, deferox
  • Z is a polymer of at least 500 Da or a C 8-18 alkyl group.
  • Z is selected from the group of optionally crosslinked polymers consisting of poly(propylene glycol), poly(ethylene glycol), dextran, chitosan, hyaluronic acid, alginate, xylan, mannan, carrageenan, agarose, cellulose, starch, hydroxyalkyl starch (HAS), poly( vinyl alcohols), poly (oxazo lines), poly(anhydrides), poly(ortho esters), poly(carbonates), poly(urethanes), poly(acrylic acids), poly(acrylamides), poly(acrylates), poly(methacrylates), poly(organophosphazenes), polyoxazoline, poly(siloxanes), poly(amides), poly(vinylpyrrolidone), poly(cyanoacrylates), poly(esters), poly(iminocarbonates), poly(amino acids), collagen, gelatin, hydrogel or a blood plasma protein, and copolymers thereof.
  • Z is a protein.
  • Z is a protein selected from the group consisting of albumin, transferrin, immunoglobulin.
  • Z is a linear or branched poly( ethylene glycol) with a molecular weight from
  • a prodrug of the present invention wherein D-H is a GLP-I receptor agonist; L is L 1 represented by formula (I) as indicated above; and Z is a hydrogel. Even more preferably, in formula (I) X is N(R 4 ), X 1 is C and X 3 is O. Even more preferably, L is represented by formula (Ia) as indicated above.
  • GLP-I is one of the intestinal peptide hormones that are released into the circulatory system after food intake. It augments the postprandial release of insulin, when nutritions (especially carbohydrates) are absorbed and their level postprandially elevated. GLP-I associates with
  • GLP-I receptor sites located on pancreatic ⁇ -cells and elevates endogenous cAMP levels in a dose dependent manner.
  • GLP-I stimulates the release of insulin.
  • a therapeutic potential for GLP-I in type 2 diabetes patients was suggested before, owing to the profound efficacy of this insulinotropic peptide to stimulate secretion of insulin when glucose levels are elevated and to cease doing so upon return to normoglycemia.
  • Exendin-4 is reported to associate with GLP-I receptors located on pancreatic beta-cells with 2.5 times higher affinity than GLP-I. In isolated rat islets and beta-cells in presence of glucose, exendin enhances secretion of insulin in a dose-dependent fashion. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide l-(7-36)-amide receptor of insulin-secreting beta-cells (see J. Biol. Chem. 268(26): 19650-19655). Studies in type 2 diabetic rodents revealed that exendin-4 is 5530-fold more potent than GLP-I in lowering blood glucose levels.
  • exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers (see e.g. Am. J. Physiol. Endocrinol. Metab. 281(1):E155-61).
  • the GLP-I receptor agonist is Exendin-4.
  • Hydrogels to be used are known in the art. Suitable hydrogels may be used which are described in WO-A 2006/003014. Accordingly, a hydrogel may be defined as a three- dimensional, hydrophilic or amphiphilic polymeric network capable of taking up large quantities of water.
  • the networks are composed of homopolymers or copolymers, are insoluble due to the presence of covalent chemical or physical (ionic, hydrophobic interactions, entanglements) crosslinks.
  • the crosslinks provide the network structure and physical integrity.
  • Hydrogels exhibit a thermodynamic compatibility with water which allow them to swell in aqueous media.
  • the chains of the network are connected in such a fashion that pores exist and that a substantial fraction of these pores are of dimensions between 1 nm and 1000 nm.
  • Another object of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a prodrug of the present invention or a pharmaceutical salt thereof together with a pharmaceutically acceptable excipient.
  • Yet another object of the present invention is a prodrug of the present invention or a pharmaceutical composition of the present invention for use as a medicament.
  • Yet another object of the present invention is a method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions comprising administering to said patient a therapeutically effective amount of a prodrug of the present invention or a pharmaceutical composition of the present invention or a pharmaceutically acceptable salt thereof.
  • Another object of the present invention is a prodrug precursor of formula Act-L, wherein L has the meaning as indicated above and Act is a leaving group.
  • Act is chloride, bromide, fluoride, nitrophenoxy, imidazolyl, N- hydroxysuccinimidyl, N-hydroxybenzotriazolyl, N-hydroxyazobenzotriazo IyI, pentafluorophenoxy, 2-thiooxo-thiazolidinyl, or N-hydroxysulfosuccinimidyl.
  • 4OkDa methoxy poly(ethylene glycol) maleimido-propionamide (PEG40kDa-maleimide) was obtained from Chirotech Technology Ltd, Cambridge, UK.
  • 2-Chlorotrityl chloride resin, Sieber amide resin and amino acids were from Merck Biosciences GmbH, Schwalbach/Ts, Germany, if not stated otherwise.
  • Fmoc-D- Homocysteine(Trt)-OH and S-Trityl-3-mercaptopropionic acid (Trt-MPA) were obtained from Bachem AG, Bubendorf, Switzerland.
  • O-(N-Fmoc-2-aminoethyl)-O'-(2-carboxyethyl)- undecaethyleneglycol (Fmoc-Pop-OH) was obtained from Polypure AS, Oslo, Norway.
  • Fmoc-4-(2-aminoethyl)-l-carboxymethyl-piperazine (Fmoc-Acp-OH) was purchased from NeoMPS SA, France, France.
  • cis-Cyclohexane-l,2-dicarboxylic anhydride was obtained from Alfa Aesar GmbH & Co KG, Düsseldorf, Germany.
  • Solid phase synthesis was performed on 2-Chlorotrityl chloride resin with a loading of 1.3 mmol/g or Sieber amide resin with a loading of 0.55 mmol/g. Syringes equipped with polypropylene frits were used as reaction vessels. Loading of the first amino acid to resins was performed according to manufacturer's instructions.
  • Fmoc deprotection For Fmoc protecting-group removal, the resin was agitated with 2/2/96 (v/v/v) piperidine/DBU/DMF (two times, 10 min each) and washed with DMF (ten times).
  • the resin was agitated with 98/2 (v/v) DMF/hydrazine hydrate (3 times, 10 min each) and washed with DMF (ten times).
  • N-terminus of a peptide was boc-protected by agitating the resin with 30 eq (boc)2 ⁇ and
  • Coupling of 3-maleimido propionic acid to free amino groups on resin was achieved by agitating resin with 2 eq of acid, 2 eq DIC and 2 eq HOBt in relation to free amino groups in DMF at room temperature. After 30 min, resin was washed with DMF (10 times).
  • Synthesis of ureas on resin was achieved by agitating resin with 2.5 eq of bis(pentafluorophenyl) carbonate, 5 eq DIEA, and 0.25 eq DMAP in relation to free amino groups in DCM/ACN 1/1 at room temperature. After 15 min resin was washed with DMF (10 times). 5 eq of amine was dissolved in DMF. Mixture was added to resin and agitated for 60 min at room temperature. Resin was washed with DMF (10 times).
  • the resin was washed with DCM, dried in vacuo and treated with 2 ml of TFA cleavage cocktail (TFA/TES/Water/DTT 95/2/2/1) per 100 mg resin for 60 min at room temperature. Volatiles were removed under a nitrogen stream. Unpolar side products and protecting groups were removed by precipitating peptide from diethyl ether. Precipitate was dried in vacuo and dissolved in ACN/water 1/1 and purified by RP-HPLC.
  • TFA cleavage cocktail TFA cleavage cocktail
  • RP-HPLC was done on a 100x20 or a 100x40 mm Cl 8 ReproSil-Pur 300 ODS-3 5 ⁇ column (Dr. Maisch, Ammerbuch, Germany) connected to a Waters 600 HPLC System and Waters
  • Electrospray ionization mass spectrometry was performed on a Waters ZQ 4000 ESI instrument and spectra were, if necessary, interpreted by Waters software MaxEnt.
  • Size exclusion chromatography was performed using an Amersham Bioscience AEKTAbasic system equipped with a Superdex200 10/300 column (Amersham Bioscience/GE Healthcare), if not stated otherwise. 10 rnM sodium phosphate, 140 mM NaCl, pH 7.4, 3 mM EDTA was used as mobile phase
  • Desalting was performed using an Amersham Bioscience AEKTAbasic system equipped with a HiPrep 26/10 Desalting column and 0.1% acetic acid in water as mobile phase.
  • hydrogel conjugates For hydrogel conjugates, compounds were suspended in buffer A and incubated at 37°C. Samples were taken after centrifugation of the suspension and analyzed by RP-HPLC at 215 nm. UV-signals correlating to liberated drug molecule were integrated and plotted against incubation time.
  • Curve-fitting software was applied to estimate the corresponding halftime of release.
  • Linker reagent 2 was synthesized on 3-chlorotrityl chloride resin (300 mg, 0.39 mmol) by loading of resin with Fmoc-Cys(Trt)-OH, fmoc deprotection, and on-resin urea formation using N,N-dimethyl-ethylenediamine as amine, cleavage from resin as depicted above and described in "Materials and Methods".
  • 0.01% HCl in water was used as solution A and 0.01% HCl in acetonitrile was used as solution B. Yield: 82 mg of HCl salt (0.16 mmol).
  • Fmoc-Acp-OH • 2 HCl (100 mg, 0.21 mmol) was suspendend in 400 ⁇ l DMF/DMSO 1/1 (v/v).
  • S-tritylcysteamine • HCl 75 mg, 0.21 mmol
  • PyBOP 109 mg, 0.21 mmol
  • DIEA 146 ⁇ l, 0.86 mmol
  • Fmoc group was removed by adding 75 ⁇ l piperidine and 25 ⁇ l DBU. After 15 min mixture was hydro lyzed and acidified (AcOH) and compound was purified by RP-HPLC. After lyophilization 98 mg (0.14 mmol, double TFA salt) were obtained.
  • 5b (7 mg, 0.010 mmol) was preactivated by incubating with PyBOP (12.5 mg, 0.024 mmol) and DIEA (5 ⁇ l, 0.03 mmol) in 200 ⁇ l of dry DMF for 45 min at RT.
  • 5a (20 mg, 0.028 mmol) and DIEA (15 ⁇ l, 0.09 mmol) were added and mixture was incubated for further 60 min.
  • Mixture was quenched with 0.5 ml of acetonitrile/acetic acid/water (1/1/1) and purified by RP-HPLC. After lyophilization 3 mg (0.0026 mmol, double TFA salt) of 5c were obtained.
  • Fmoc-Asp(tBu)-OH (411 mg, 1 mmol), HOBt (153 mg, 1 mmol), and DIC (160 ⁇ l, 1 mmol) were dissolved in 2 ml of DMF and incubated for 10 min at RT. N,N-dimethyl ethylenediamine (160 ⁇ l, 1.5 mmol) was added and stirred at RT for 30 min. Acetic acid (300 ⁇ l) was added and Fmoc-Asp(tBu)-NH-(CH 2 )2-N(CH 3 )2 was purified by RP-HPLC.
  • Fmoc-Asp(H)-NH-(CH 2 ) 2 -NH 2 (140 mg, 0.27 mmol, TFA salt) was dissolved in 1 ml of DMF and DIEA (140 ⁇ l, 0.81 mmol) and boc 2 ⁇ (100 mg, 0.46 mmol) added. The solution was stirred at RT for 15 min and then acidified with acetic acid (300 ⁇ l). 7a was purified by RP- HPLC. Yield 7a: 120 mg (0.24 mmol)
  • Exendin-4 on resin (40 mg, 4 ⁇ mol) and incubated for 1 h at room temperature. Resin was washed ten times with DMF and then incubated for 5 min with 500 ⁇ l of 1/1/2 acetic anhydride/pyridine/DMF. Resin was washed 10 times with DMF and fmoc group was removed. Trt-mercaptopropionic acid was coupled and 8a was cleaved from resin and purified by RP-HPLC.
  • 8b was synthesized as described above for 8a except for the use of 7b instead of 7a.
  • 9a was purified by ion exchange chromatography using 10 mM sodium citrate pH 3 as solvent A and 10 mM sodium citrate pH 3 and 1 M NaCl as solvent B and a step-gradient (0 to 40% B). Fractions containing 9a were desalted and lyophilized:
  • Trt-mercaptopropionic acid was coupled according to standard coupling method and resin was washed five times with DMF and ten times with DCM. Mmt protecting group of Lys27 was removed by incubation of resin five times in 2 ml of 9/1 (v/v) DCM/HFIP for 5 min. Resin was washed five times with DCM and five times with DMF and 5,6-carboxy-flourescein-NHS ester (20 mg, 42 ⁇ mol) and DIEA (20 ⁇ l, 115 ⁇ l) in 300 ⁇ l DMF were added to resin and incubated for 30 min. 12a was cleaved from resin and purified by RP-HPLC Yield: 12 mg
  • Trt-mercaptopropionic acid was coupled according to standard coupling method to side-chain protected Exendin-4 on resin (120 mg, 12 ⁇ mol). Mmt protecting group removal of Lys27 and
  • 12d was synthesized as described for 12c except for the use of GRF(I -29) on resin (120mg,
  • N,N-dimethylethylenediamine (198 ⁇ L, 1.8 mmol) and NaCNBH 3 (58 mg, 0.9 mmol) were dissolved in methanol (5 mL) and brought to pH 5.5 by addition of AcOH (250 ⁇ L).
  • a suspension of 2,4,6, -trimethoxybenzaldehyde (294 mg, 1.5 mmol) in EtOH (5 mL) was added and the reaction was stirred at RT for 1 h.
  • 5 N HCl (0.5 mL) was added and the mixture was stirred for further 12 h.
  • the solvent was removed under reduced pressure; the residue was dissolved in sat. NaHCO 3 and extracted 3x with DCM.
  • the combined organic phases were dried over NaSO 4 and the solvent was evaporated under reduced pressure. Yield: 303 mg (1.13 mmol)
  • Fmoc-Asp(OtBu)-N(Tmob)CH 2 CH 2 N(CH 3 ) 2 225 mg, 0.29 mmol was dissolved in a solution of piperidine (50 ⁇ L) and DBU (15 ⁇ L) in DMF (1.5 mL). The mixture was stirred at
  • the TFA salt OfH-ASp(OtBu)-N(TmOb)CH 2 CH 2 N(CHs) 2 (114 mg, 0.21 mmol) was dissolved in sat. NaHCO 3 (10 mL) and extracted 3x with DCM (3x 10 mL). The combined organic layers were dried over NaSO 4 and the solvent was removed under reduced pressure. The residue was dissolved in DMF (1.0 mL), 6-tritylmercaptohexanoic acid (121 mg, 0.31 mmol), HATU (118 mg, 0.31 mmol) and DIEA (108 ⁇ L, 0.62 mmol) were added. The mixture was stirred for 30 min.
  • TrtS(CH 2 ) 5 CONH-Asp(OtBu)- N(TmOb)CH 2 CH 2 N(CHs) 2 was purified by RP-HPLC. Yield: 95 mg (0.10 mmol, TFA salt)
  • TrtS(CH 2 ) 5 CONH- ASp(OtBu)-N(TmOb)CH 2 CH 2 N(CHs) 2 (95 mg, 0.10 mmol) was dissolved in a 3:1 mixture of MeOH/H 2 O (1.0 mL), LiOH (7.4 mg, 0.31 mmol) was added and the mixture was stirred for 5 h at 60 0 C. AcOH was added (100 ⁇ L) and 17a was purified by RP- HPLC.
  • 19b was synthesized as described for 19a except for the use of 18b instead of 18a.
  • Fmoc-Asp(NH(CH 2 )2N(CH 3 )-boc)OtBu (91 mg, 0.13 mmol) was dissolved in DMF (1.0 mL), piperidine (50 ⁇ L) and DBU (15 ⁇ L) were added and the mixture was stirred for 45 min at RT. AcOH (100 ⁇ L ) was added and NH 2 -Asp(NH(CH 2 ) 2 N(CH 3 )-boc)OtBu was purified by RP-HPLC.
  • 6-Tritylmercaptohexanoic acid 200 mg, 0.51 mmol
  • (PIpO) 2 CO 202 mg, 0.51 mmol
  • collidine 340 ⁇ L, 2.65 mmol
  • the mixture was added to a solution of Fmoc-Lys-OH (170 mg, 0.46 mmol) in H 2 O/pyridine/tBuOH (3:3:1, 6 mL).
  • the reaction was heated at 60 0 C for 2h, diluted with EtOAc, extracted 2x with 0.1M H 2 SO 4 , 2x with brine and dried over Na 2 SO 4 .
  • the solvent was evaporated under reduced pressure and the residue was purified by RP-HPLC. Yield: 109 mg
  • 25c was synthesized as described for 25a except for the use of 24c instead of 24a. Yield: 1.3 mg
  • 26c was synthesized as described for 26a except for the use of 25c instead of 25a.
  • H 25a (2.0 mg) was dissolved in 1 :1 H 2 0/MeCN containing 0.1 % TFA (200 ⁇ l).
  • the solution was incubated at RT, after 5 min AcOH (20 ⁇ l) was added and 27a was purified by cation exchange chromatography, desalted and lyophilized.
  • 27b was synthesized as described for 27a except for the use of 25b instead of 25a.
  • 27c was synthesized as described for 27a except for the use of 25c instead of 25a.
  • JV-Boc-ethylenediamine (81 ⁇ l, 0.51 mmol) was added to a solution of Br-(CH 2 )s-CONH-
  • Boc-NH-(CH 2 ) 2 -N(CH 3 )-(CH 2 ) 5 -CONH-(CH 2 ) 2 -STrt (62.8 mg, 0.11 mmol) was dissolved in
  • 31b 31b was synthesized as described for 31a except for the use of 30b instead of 30a. Yield: 16.8 mg
  • JV-Alloc-ethylenediamine HCl-salt (43.5 mg, 0.24 mmol) and DIEA (38 ⁇ l, 0.22 mmol) were added to a solution of Br-(CH 2 ) 2 CONH-(CH 2 )-STrt (100 mg, 0.22 mmol) and Na 2 CO 3 (93 mg, 0.87 mmol) in DMF (1 ml). The reaction mixture was stirred for 10 h at 70 0 C.
  • 33a was synthesized as described for 30a except for the use of 32 instead of 28.
  • 34b was synthesized as described for 34a except for the use of 33b instead of 33a. Yield: 11.5 mg
  • Linker-exendin conjugates were synthesized according to general synthesis method A, B, C, D, E or F.
  • Diacid anhydride (0.2 mmol) and pyridine (0.2 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to exendin-4 on resin (2 ⁇ mol) and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). PyBOP (0.1 mmol), HOBt (0.1 mmol), and collidine (0.4 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to resin and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). Diamine (0.1 mmol) and DIEA (0.3 mmol) were dissolved in a mixture of 0.4 ml of DMF and 0.4 ml of EtOH.
  • Exendin- linker conjugates were cleaved and purified by RP-HPLC as described in "Materials and Methods".
  • maleimide-functionalized hydrogel microparticles were synthesized as described in EP 1 625 856 A1. 30 mg of maleimide-derivatized hydrogel microparticles (loading 40 ⁇ mol/g, 1.2 ⁇ mol) were reacted with 6 mg of compound 25a (1.32 ⁇ mol, 1.1 eq) in 600 ⁇ l 20/80 (v/v) acetonitrile/50 mM phosphate buffer (pH 7.4) for 10 min to give exendin- linker loaded hydrogel microparticles 39. The loaded hydrogel 39 was washed 5 times with 50/50 (v/v) acetonitrile/water and three times with water.
  • 46 46 was synthesized as described for 42 except for the use of 45 instead of 41.
  • Tritylsulf ⁇ de (247 mg, 0.89 mmol) was suspended in 1 ml DMSO.
  • DBU 152 ⁇ l, 1.02 mmol
  • 6-bromohexan-l-ol 173 mg, 0.96
  • Reaction mixture was dissolved in 20 ml ethylacetate and washed with 1 N H 2 SO 4 (2x) and brine (3x). Organic layer was dried (Na 2 SO 4 ) and volatiles were removed in vacuo. Product was purified by flash chromatography on silica (heptane/ AcOEt 1/1).
  • Fmoc- AIa-OH 250 mg, 0.8 mmol
  • DIEA 170 ⁇ L, 1,0 mmol
  • 2-chlorotrityl chloride resin 312 mg, 1.3 mmol/g
  • Methanol 0.6 mL
  • the resin was washed with DCM (1Ox) and DMF (1Ox). Fmoc-deprotection and urea formation was achieved according to general procedures (see Materials and Methods) by reaction with ethylene diamine.
  • Release kinetics in vivo were determined by comparing the pharmacokinetics of 13a with the pharmacokinetics of 13c and 13b with 13d, respectively, after intravenous injection into rat. Animal studies were performed at Heidelberg Pharma AG, Heidelberg, Germany. 13a (27 mg) was dissolved in 3.5 ml PBS and 500 ⁇ l of the resulting solution were injected intravenously into six rats each. Male SD rats with approximately 270 g weight were used.
  • Pharmacokinetics of 13c were determined as described for 13a.
  • Pharmacokinetics of 13b and 13d were determined as described for 13a, except for the use of 20 mg 13 b and 13d each in 2.5 ml PBS and four rats.
  • Linker hydrolysis half-life was calculated from the ratio of fluorescence of 13a compared to fluorescence of 13c and 13b compared to 13d, respectively, at the respective time points.
  • Half-life of in vivo linker hydrolysis was determined to be 115 h and 160 h for 13a and 13b, respectively, which is in excellent correlation to the half-life of in vitro linker hydrolysis of 12O h and 16O h for 13a and 13b, respectively.
  • Fig. 3 shows in vivo and in vitro linker cleavage data of 13b, wherein in vivo (triangles) and in vitro (diamonds) cleavage kinetics are shown by semilogarithmic representation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R 1a, R 2, R2a , R3, R 3a, X, X 1, X 2, X 3 have the meaning as indicated in the description and the claims and wherein L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group.The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

Description

Prodrug comprising a drug linker conjugate
The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
To enhance physicochemical or pharmacokinetic properties of a drug in vivo such drug can be conjugated with a carrier.
Typically, carriers in drug delivery are either used in a non-covalent fashion, with the drug physicochemically formulated into a solvent-carrier mixture, or by covalent attachment of a carrier reagent to one of the drug's functional groups.
However the non-covalent approach requires a highly efficient drug encapsulation to prevent uncontrolled, burst-type release of the drug. Restraining the diffusion of an unbound, water soluble drug molecule requires strong van der Waals contacts, frequently mediated through hydrophobic moieties. Many conformationally sensitive drugs, such as proteins or peptides, are rendered dysfunctional during the encapsulation process and/or during subsequent storage of the encapsulated drug. In addition, such amino-containing drugs readily undergo side reactions with carrier degradation products (see, for example, D.H. Lee et al., J. Contr. ReL, 2003, 92, 291-299). Furthermore, dependence of the release mechanism of the drug upon biodegradation may cause interpatient variability.
Alternatively, the drugs may be conjugated to a carrier through covalent bonds. This approach is applied to various classes of molecules, from so-called small molecules, through natural products up to larger proteins. Covalent drug carrier conjugates can be divided into two groups. Firstly, conjugates, where the covalent bond between carrier and drug is mostly present during the action of the drug ("permanent covalent bond"), i.e. a derivative of the drug exhibits its pharmacological effects as it is known for the drug as such. Secondly, the covalent bond is mostly previously cleaved to release the drug as such, which can exhibit its known pharmacological effects. In the latter case the covalent drug carrier conjugate is called carrier linked prodrug or carrier prodrug. In order to ensure cleavage of the covalent bond between carrier and drug easy removal of said bond in vivo is required to release the drug (prodrug activation).
Prodrug activation may occur by enzymatic or non-enzymatic cleavage of the bond between the carrier and the drug molecule, or a sequential combination of both, i.e. an enzymatic step followed by a non-enzymatic rearrangement.
Enzymatically induced prodrug activation is characterized in that the cleavage in enzyme-free in-vitro environment such as an aqueous buffer solution, of, e.g., an ester or amide may occur, but the corresponding rate of hydrolysis may be much too slow and not therapeutically useful. In an in-vivo environment, esterases or amidases are typically present and the esterases and amidases may cause significant catalytic acceleration of the kinetics of hydrolysis from twofold up to several orders of magnitude. Therefore, the cleavage is predominantly controlled by the enzymatic reaction.
A major drawback of predominantly enzymatic cleavage is interpatient variability. Enzyme levels may differ significantly between individuals resulting in biological variation of prodrug activation by the enzymatic cleavage. The enzyme levels may also vary depending on the site of administration. For instance it is known that in the case of subcutaneous injection, certain areas of the body yield more predictable therapeutic effects than others. To reduce this unpredictable effect, non-enzymatic cleavage or intramolecular catalysis is of particular interest.
Therefore, enzyme-independent autocatalytic cleavage of carrier and biologically active moiety is preferred. In most cases this is achieved by an appropriately designed linker moiety between the carrier and the biologically active moiety, which is directly attached to the functional group of a biologically active moiety via covalent bond.
Specific linker types are known in the art. Y. Sohma et al, J. Med. Chem. 46 (2003), 4124-4135 describe ester based prodrugs, where the carrier is water-soluble and the biologically active moiety is derived from HIV-I protease inhibitor KNI-727. The linker used is attached to the biologically active moiety via ester group. The mechanism of this prodrug system is cyclization-activation by cyclic imide formation for the cleavage of ester bonds. However this is disadvantageous because of the instability of the ester functional group. Furthermore, ester groups may be less chemoselectively addressable for the conjugation of the carrier or linker and the drug.
A.J. Garman et al. (AJ. Garman, S.B. Kalindjan, FEBS Lett. 1987, 223 (2), 361-365
1987) use PEG5000-maleic anhydride for the reversible modification of amino groups in tissue-type plasminogen activator and urokinase. Regeneration of functional enzyme from PEG-uPA conjugate upon incubation at pH 7.4 buffer by cleavage of the maleamic acid linkeage follows first order kinetics with a half- life of 6.1 h. A disadvantage of the maleamic acid linkage is the lack of stability of the conjugate at lower pH values. This limits the applicability of the maleamic acid linkage to biologically active agents which are stable at basic (high) pH values, as purification of the biologically active agent polymer conjugate has to be performed under basic (high pH) conditions to prevent premature prodrug cleavage.
In WO-A 2004/108070 prodrug system based on N,N-bis-(2-hydroxyethyl)glycine amide (bicine) linker is described. In this system two PEG carrier molecules are linked to a bicine molecule coupled to an amino group of the drug molecule. The first two steps in prodrug activation is the enzymatic cleavage of the first linkages connecting both PEG carrier molecules with the hydroxy groups of the bicine activating group. Different linkages between PEG and bicine are described resulting in different prodrug activation kinetics. The second step in prodrug activation is the cleavage of the second linkage connecting the bicine activating group to the amino group of the drug molecule. The main disadvantage of this system is the connection of the polymer to the bicine linker resulting in a slow hydrolysis rate of this second bicine amide linkage (tl/2 > 3 h in phosphate buffer). Consequently the release of a bicine-modified prodrug intermediate may show different pharmacokinetic, immunogenic, toxicological and pharmacodynamic properties as compared to the parent native drug molecule.
Another bicine-based system is described in WO-A 2006/136586.
Accordingly, there is a need for alternative carrier-linked prodrugs, where the linker allows an autocatalytic cleavage to release a drug in an unmodified form without remaining residues originating from the linker. Thus, an object of the present invention is to provide such drug linker conjugates, where the linker is covalently attached via a cleavable bond to a biologically active moiety (representing the drug after release), and where the linker is further covalently attached via a permanent bond to a carrier directly or via a spacer to form the carrier- linked prodrug.
This object is achieved by a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein
-D is a nitrogen containing biologically active moiety; and
-L is a non-bio logically active linker moiety -L1 represented by formula (I),
Figure imgf000005_0001
wherein the dashed line indicates the attachment to the nitrogen of the biologically active moiety by forming an amide bond;
X is C(R4R4a); N(R4); O; C(R4R4a)-C(R5R5a); C(R5R5a)-C(R4R4a); C(R4R4a)-N(R6); N(R6)- C(R4R4a); C(R4R4a)-O; or O-C(R4R4a);
XI is C; or S(O);
X2 is C(R7, R7a); or C(R7, R7a)-C(R8, R8a);
X3 is O; S; or N-CN;
R1, Rla, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6, R7, R7a, R8, R8a are independently selected from the group consisting of H; and Ci_4 alkyl;
Optionally, one or more of the pairs Rla/R4a, Rla/R5a, R4a/R5a, R7a/R8a form a chemical bond; Optionally, one or more of the pairs RVRla, R2/R2a, R4/R4a, R5/R5a, R7/R7a, R8/R8a are joined together with the atom to which they are attached to form a C3_7 cycloalkyl; or 4 to 7 membered heterocyclyl;
Optionally, R4/R6 are joined together with the atoms to which they are attached to form a saturated 4 to 7 membered heterocyclyl;
Optionally, one or more of the pairs RVR4, RVR5, RVR6, R4/R5, R4/R6, R7/R8, R2/R3 are joined together with the atoms to which they are attached to form a ring A;
Optionally, R3/R3a are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle;
A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 4 to 7 membered heterocyclyl; and 9 to 11 membered heterobicyclyl; and
wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein
L2 is a single chemical bond or a spacer; and Z is a carrier group.
It was surprisingly found, that the scope of cyclization-activation by cyclic imide formation can be extended from ester to even carrier- linked amide prodrugs, despite the much greater stability of the amide bond under aqueous conditions. It was observed that N5N'- biscarboxamides linked to a nucleophile carrying moiety through one amide bond and to the drug molecule through the second amide bond exhibit autohydro lysis in a range that is useful for prodrug applications. In addition, it was discovered that linkers can be designed that include a carrier permanently attached to the N5N' biscarboxamide motif in such a fashion that cyclic imide formation can be employed as a self-activation principle in carrier- linked amide prodrug design. Examples for such preferred cyclic cleavage products are substituted succinimide or glutarimide ring structures. Prerequisite for such cyclization activation is the presence of an amine-containing nucleophile in the linker structure and another amide bond which is not the amide prodrug bond but an amide bond substituted with a hydrogen atom.
In case of succinimide- or a glutarimide-activated prodrug cleavage, the amine-containing nucleophile serves as a neighbouring group to enhance the nucleophilicity of the nitrogen contained in the permanent amide bond which in turn attacks the prodrug amide carbonyl group and consequently induces intramolecular acylation of the permanent amide bond generating the cyclic imide ring.
Therefore preferred linker structures comprise a permanent linkage to a carrier, an amine- containing nucleophile, and a permanent amide bond with a hydrogen attached to the nitrogen of the amide bond. Corresponding carrier- linked prodrugs comprise a linker containing a permanent linkage to a carrier, an amine-containing nucleophile and said permanent amide bond, and a nitrogen containing biologically active moiety derived from the drug conjugated to the linker by means of a cleavable amide bond.
Fig. 1 shows an example of the cleavage resulting in a cyclic imide. The nitrogen of the biologically active moiety is shown as hydrogen containing amine, which results in a drug having a primary amine functional group. However also, e.g., a secondary amine may be part of the drug. For simplification reasons the one to four mandatory substituents L2-Z including the carrier are not shown.
Preferred properties of the prodrug are given by a half- life of hydrolysis in aqueous buffer at pH 7.4 and 37°C between 1 h and 3 months; similar rates of hydrolysis under physiological conditions in buffer and plasma.
The prodrug according to the present invention may show excellent in vivo/in vitro correlation of linker cleavage, a high degree of enzyme independence and can be stored at lower pH (pH dependent cleavage).
Within the meaning of the present invention the terms are used as follows. "Biologically active moiety D" means the part of the drug linker conjugate, which results after cleavage in a drug D-H of known biological activity.
"Non-active linker" means a linker which does not show the pharmacological effects of the drug derived from the biologically active agent.
"Alkyl" means a straight-chain or branched carbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent.
"Ci_4 alkyl" means an alkyl chain having 1 - 4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl tert-butyl, or e.g. - CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, -C(CH3)2-, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a Ci_4 alkyl carbon may be replaced by a substituent.
"Ci_6 alkyl" means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: Ci_4 alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl; tert-butyl, n-pentyl, n-hexyl, or e.g. -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, - C(CH3)2-, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a Ci_6 alkyl carbon may be replaced by a substituent.
Accordingly, "C1-18 alkyl" means an alkyl chain having 1 to 18 carbon atoms and "C8-18 alkyl" means an alkyl chain having 8 to 18 carbon atoms. Accordingly, "Ci_5o alkyl" means an alkyl chain having 1 to 50 carbon atoms.
"C2_5o alkenyl" means a branched or unbranched alkenyl chain having 2 to 50 carbon atoms, e.g. if present at the end of a molecule: -CH=CH2, -CH=CH-CH3, -CH2-CH=CH2, -CH=CH- CH2-CH3, -CH=CH-CH=CH2, or e.g. -CH=CH-, when two moieties of a molecule are linked by the alkenyl group. Each hydrogen of a C2_5o alkenyl carbon may be replaced by a substituent as further specified. Accordingly, the term "alkenyl" relates to a carbon chain with at least one carbon carbon double bond. Optionally, one or more triple bonds may occur.
"C2_5o alkynyl" means a branched or unbranched alkynyl chain having 2 to 50 carbon atoms, e.g. if present at the end of a molecule: -C≡CH, -CH2-C≡CH, CH2-CH2-C≡CH, CH2-C≡C- CH3, or e.g. -C≡C- when two moieties of a molecule are linked by the alkynyl group. Each hydrogen of a C2-50 alkynyl carbon may be replaced by a substituent as further specified. Accordingly, the term "alkynyl" relates to a carbon chaim with at lest one carbon carbon triple bond. Optionally, one or more double bonds may occur.
"C3_7 cycloalkyl" or "C3_7 cycloalkyl ring" means a cyclic alkyl chain having 3 to 7 carbon atoms, which may have carbon-carbon double bonds being at least partially saturated, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent. The term "C3_7 cycloalkyl" or "C3_7 cycloalkyl ring" also includes bridged bicycles like norbonane or norbonene. Accordingly, "C3_5 cycloalkyl" means a cycloalkyl having 3 to 5 carbon atoms.
Accordingly, "C3_io cycloalkyl" means a cyclic alkyl having 3 to 10 carbon atoms, e.g. C3_7 cycloalkyl; cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl. The term "C3-10 cycloalkyl" also includes at least partially saturated carbomono- and -bicycles.
"Halogen" means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
"4 to 7 membered heterocyclyl" or "4 to 7 membered heterocycle" means a ring with 4, 5, 6 or 7 ring atoms that may contain up to the maximum number of double bonds (aromatic or non- aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)2-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 4 to 7 membered heterocycles are azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydro furan, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine or homopiperazine. "9 to 11 membered heterobicyclyl" or "9 to 11 membered heterobicycle" means a heterocyclic system of two rings with 9 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)2-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 9 to 11 membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine. The term 9 to 11 membered heterobicycle also includes spiro structures of two rings like l,4-dioxa-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.
In case the compounds according to formula (I) contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of the formula (I) which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the formula (I) simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
The term "pharmaceutically acceptable" means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.
"Pharmaceutical composition" means one or more active ingredients, and one or more inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable excipient (pharmaceutically acceptable carrier).
The term "excipient" refers to a diluent, adjuvant, or vehicle with which the therapeutic is administered. Such pharmaceutical excipient can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred excipient when the pharmaceutical composition is administered orally. Saline and aqueous dextrose are preferred excipients when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid excipients for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and excipients such as triglycerides. Oral formulation can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical excipients are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of excipient so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
Preferably, X3 is O.
Preferably, X is N(R4), X1 is C and X3 is O.
Preferably, X2 is C(R7R7a).
Preferably, L1 is selected from the group consisting of
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000013_0002
Figure imgf000014_0001
wherein R is H; or Ci-4 alkyl; Y is NH; O; or S; and R1, Rla, R2, R2a, R3, R3a, R4, X, X1, X2 have the meaning as indicated above.
Even more preferred, L1 is selected from the group consisting of
Figure imgf000014_0002
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
wherein R has the meaning as indicated above.
At least one (up to four) hydrogen is replaced by a group L2-Z. In case more than one group L2-Z is present each L2 and each Z can be selected independently. Preferably, only one group L2-Z is present resulting in the formula D-L1-L2-Z.
In general, L2 can be attached to L1 at any position apart from the replacement of the hydrogen marked with an asterisk in formula (I). Preferably, one to four of the hydrogen given by R, R1 to R8 directly or as hydrogen of the Ci_4 alkyl or further groups and rings given by the definition of R and R1 to R8 are replaced by L2-Z.
Furthermore, L1 may be optionally further substituted. In general, any substituent may be used as far as the cleavage principle is not affected.
Preferably, one or more further optional substituents are independently selected from the group consisting of halogen; CN; COOR9; OR9; C(O)R9; C(O)N(R9R9a); S(O)2N(R9R9a); S(O)N(R9R9a); S(O)2R9; S(O)R9; N(R9)S(O)2N(R9aR9b); SR9; N(R9R9a); NO2; OC(O)R9; N(R9)C(O)R9a; N(R9)S(O)2R9a; N(R9)S(O)R9a; N(R9)C(O)OR9a; N(R9)C(O)N(R9aR9b); OC(O)N(R9R9a); T; Ci-50 alkyl; C2-50 alkenyl; or C2-50 alkynyl, wherein T; Ci-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R10, which are the same or different and wherein Ci-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of T, -C(O)O-; -0-; -C(O)-; - C(O)N(R11)-; -S(O)2N(R11)-; -S(O)N(R11)-; -S(O)2-; -S(O)-; -N(R1 ^S(O)2N(R1 la)-; -S-; - N(R11)-; -OC(O)R11; -N(Rπ)C(0)-; -N(R1 ^S(O)2-; -N(R1 ^S(O)-; -N(R1 ^C(O)O-; - N(R1 ^C(O)N(R11")-; and -OC(O)N(R11R1 la); R9, R9a, R9b are independently selected from the group consisting of H; T; and Ci_so alkyl; C2- 50 alkenyl; or C2-50 alkynyl, wherein T; Ci .50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R10, which are the same or different and wherein Ci_so alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of T, -C(O)O-; -O-; -C(O)-; -C(O)N(R11)-; -S(O)2N(R11)-;
Figure imgf000019_0001
T is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 4 to 7 membered heterocyclyl; or 9 to 11 membered heterobicyclyl, wherein T is optionally substituted with one or more R10, which are the same or different;
R10 is halogen; CN; oxo (=0); COOR12; OR12; C(O)R12; C(O)N(R12R12a); S(O)2N(R12R12a);
Figure imgf000019_0002
alkyl, wherein Ci-6 alkyl is optionally
Figure imgf000019_0003
substituted with one or more halogen, which are the same or different;
R11, Rl la, R12, R12a, R12b are independently selected from the group consisting of H; or Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
The term "interrupted" means that between two carbons a group is inserted or at the end of the carbon chain between the carbon and hydrogen.
L2 is a single chemical bond or a spacer. In case L2 is a spacer, it is preferably defined as the one or more optional substituents defined above, provided that L2 is substituted with Z.
Accordingly, when L2 is other than a single chemical bond, L2-Z is COOR9; OR9; C(O)R9;
Figure imgf000019_0004
( ); ( ) ; ( ) ( ) ; ( ) ( )2 ; ( ) ( ) ; ( ) ( ) ;
Figure imgf000019_0005
alkenyl; or C2-50 alkynyl, wherein T; Ci_5o alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R10, which are the same or different and wherein Ci .50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -
Figure imgf000020_0001
R9, R9a, R9b are independently selected from the group consisting of H; Z; T; and Ci_so alkyl; C2_5o alkenyl; or C2_so alkynyl, wherein T; Ci_so alkyl; C2_so alkenyl; and C2_so alkynyl are optionally substituted with one or more R10, which are the same or different and wherein Ci_so alkyl; C2_so alkenyl; and C2_so alkynyl are optionally interrupted by one or more groups selected from the group consisting of
Figure imgf000020_0003
( ) ( ) ( ) ( 11) ( ) ( 11) - ;
Figure imgf000020_0002
T is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 4 to 7 membered heterocyclyl; or 9 to 11 membered heterobicyclyl, wherein t is optionally substituted with one or more R10, which are the same or different;
Figure imgf000020_0004
alkyl is optionally substituted with one or more halogen, which are the same or different;
R11, Rl la, R12, R12a, R12b are independently selected from the group consisting of H; Z; or Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
provided that one of R9, R9a, R9b, R10, R11, Rl la, R12, R12a, R12b is Z.
More preferably, L2 is a Ci_2o alkyl chain, which is optionally interrupted by one or more groups independently selected from -0-; and C(0)N(R3aa); optionally substituted with one or more groups independently selected from OH; and C(O)N(R3aaR3aaa); and wherein R3aa, R3aaa are independently selected from the group consisting of H; and Ci_4 alkyl. Preferably, L2 has a molecular weight in the range of from 14 g/mol to 750 g/mol.
Preferably, L2 is attached to Z via a terminal group selected from
Figure imgf000021_0001
In case L2 has such terminal group it is furthermore preferred that L2 has a molecular weight in the range of from 14 g/mol to 500 g/mol calculated without such terminal group.
Preferably, L is represented by formula (Ia)
Figure imgf000021_0002
wherein R4, L2, and Z have the meaning as indicated above, and wherein R3aa, R3aaa are independently selected from the group consisting of H; and Ci_4 alkyl; or are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle. Preferably, R4 is H; or methyl.
Preferably, L is represented by formula (Ib)
Figure imgf000021_0003
wherein R1, Rla, R4, L2 and Z have the meaning as indicated above, and wherein R3aa is H; or Ci_4 alkyl. Preferably, R4 is H; or methyl.
Preferably, R1 in formula (I) is L2-Z.
Preferably, R3 in formula (I) is L2-Z. Preferably, R3, R3a in formula (I) are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle, wherein the heterocycle is substituted with iΛz.
Preferably, D-H is a small molecule bioactive agent or a biopolymer.
Preferably, D-H is a biopolymer selected from the group of biopolymers consisting of proteins, polypeptides, oligonucleotides, and peptide nucleic acids.
"Oligonucleotides" means either DNA, RNA, single-stranded or double-stranded, siRNA, miRNA, aptamers, and any chemical modifications thereof with preferably 2 to 1000 nucleotides. Modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5- position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5 -io do -uracil; backbone modifications, methylations, unusual base- pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping and change of stereochemistry.
Preferably, D-H is a polypeptide selected from the group of polypeptides consisting of ACTH, adenosine deaminase, agalsidase, alfa-1 antitrypsin (AAT), alfa-1 proteinase inhibitor (API), alteplase, amylins (amylin, symlin), anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal, and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, atosiban, biphalin, bivalirudin, bone-morphogenic proteins, bovine pancreatic trypsin inhibitor (BPTI), cadherin fragments, calcitonin (salmon), collagenase, complement Cl esterase inhibitor, conotoxins, cytokine receptor fragments, DNase, dynorphine A, endorphins, enfuvirtide, enkephalins, erythropoietins, exendins, factor VII, factor Vila, factor VIII, factor Villa, factor IX, fibrinolysin, fibroblast growth factor (FGF), growth hormone releasing peptide 2 (GHRP2), fusion proteins, follicle- stimulating hormones, gramicidin, ghrelin, desacyl-ghrelin, granulocyte colony stimulating factor (G- CSF), galactosidase, glucagon, glucagon-like peptides, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GM-CSF), human heat shock proteins (HSP), phospholipase-activating protein (PLAP), gonadotropin chorionic (hCG), hemoglobins, hepatitis B vaccines, hirudin, human serine protease inhibitor, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukins (1 alfa, 1 beta, 2, 3, 4, 6, 10, 11, 12, 13, 21), IL-I receptor antagonist (rhlL-lra), insulins, insulin like growth factors, insulin-like growth factor binding protein (rhl GFBP), interferons (alfa 2a, alfa 2b, alfa 2c, beta Ia, beta Ib, gamma Ia, gamma Ib), intracellular adhesion molecule, keratinocyte growth factor (KGF), P-selectin glycoprotein ligand (PSGL), transforming growth factors, lactase, leptin, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptides (ANP, BNP, CNP and fragments), neuropeptide Y, pancrelipase, pancreatic polypeptide, papain, parathyroid hormone, PDGF, pepsin, peptide YY, platelet activating factor acetylhydrolase (PAF-AH), prolactin, protein C, thymalfasin, octreotide, secretin, sermorelin, soluble tumor necorsis factor receptor (TNFR), superoxide dismutase (SOD), somatropins (growth hormone), somatoprim, somatostatin, streptokinase, sucrase, terlipressin, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrotropin, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), TSH, urodilatin, urate oxidase, urokinase, vaccines, vascular endothelial growth factor (VEGF), vasoactive intestinal peptide, vasopressin, ziconotide, lectin and ricin.
Preferably, D-H is a protein prepared by recombinant DNA technologies.
Preferably, D-H is a protein selected from the group of proteins consisting of antibody fragments, single chain antigen binding proteins, catalytic antibodies and fusion proteins.
Preferably, D-H is a small molecule bioactive agent selected from the group of agents consisting of central nervous system-active agents, anti-infective, anti-allergic, immunomodulating, anti-obesity, anticoagulants, antidiabetic, anti-neoplastic, antibacterial, anti-fungal, analgesic, contraceptive, anti-inflammatory, steroidal, vasodilating, vasoconstricting, and cardiovascular agents with at least one primary or secondary amino group.
Preferably, D-H is a small molecule bioactive agent selected from the group of agents consisting of acarbose, alaproclate, alendronate, amantadine, amikacin, amineptine, aminoglutethimide, amisulpride, amlodipine, amotosalen, amoxapine, amoxicillin, amphetamine, amphotericin B, ampicillin, amprenavir, amrinone, anileridine, apraclonidine, apramycin, articaine, atenolol, atomoxetine, avizafone, baclofen, benazepril, benserazide, benzocaine, betaxolol, bleomycin, bromfenac, brofaromine, carvedilol, cathine, cathinone, carbutamid, cefalexine, clinafloxacin, ciprofloxacin, deferoxamine, delavirdine, desipramine, daunorubicin, dexmethylphenidate, dexmethylphenidate, diaphenylsulfon, dizocilpine, dopamin, dobutamin, dorzolamide, doxorubicin, duloxetine, eflornithine, enalapril, epinephrine, epirubicin, ergoline, ertapenem, esmolol, enoxacin, ethambutol, fenfluramine, fenoldopam, fenoterol, fmgolimod, flecainide, fluvoxamine, fosamprenavir, frovatriptan, furosemide, fluoexetine, gabapentin, gatifloxacin, gemiflocacin, gentamicin, grepafloxacin, hexylcaine, hydralazine, hydrochlorothiazide, icofungipen, idarubicin, imiquimod, inversine, isoproterenol, isradipine, kanamycin A, ketamin, labetalol, lamivudine, levobunolol, levodopa, levothyroxine, lisinopril, lomefloxacin, loracarbef, maprotiline, mefloquine, melphalan, memantine, meropenem, mesalazine, mescaline, methyldopa, methylenedioxymethamphetamine, metoprolol, milnacipran, mitoxantron, moxifloxacin, norepinephrine, norfloxacin, nortriptyline, neomycin B, nystatin, oseltamivir, pamidronic acid, paroxetine, pazufloxacin, pemetrexed, perindopril, phenmetrazine, phenelzine, pregabalin, procaine, pseudoephedrine, protriptyline, reboxetine, ritodrine, sabarubicin, salbutamol, serotonin, sertraline, sitagliptin, sotalol, spectinomycin, sulfadiazin, sulfamerazin, sertraline, sprectinomycin, sulfalen, sulfamethoxazol, tacrine, tamsulosin, terbutaline, timolol, tirofϊban, tobramycin, tocainide, tosufloxacin, trandolapril, tranexamic acid, tranylcypromine, trimerexate, trovafloxacin, valaciclovir, valganciclovir, vancomycin, viomycin, viloxazine, and zalcitabine.
Preferably, Z is a polymer of at least 500 Da or a C8-18 alkyl group.
Preferably, Z is selected from the group of optionally crosslinked polymers consisting of poly(propylene glycol), poly(ethylene glycol), dextran, chitosan, hyaluronic acid, alginate, xylan, mannan, carrageenan, agarose, cellulose, starch, hydroxyalkyl starch (HAS), poly( vinyl alcohols), poly (oxazo lines), poly(anhydrides), poly(ortho esters), poly(carbonates), poly(urethanes), poly(acrylic acids), poly(acrylamides), poly(acrylates), poly(methacrylates), poly(organophosphazenes), polyoxazoline, poly(siloxanes), poly(amides), poly(vinylpyrrolidone), poly(cyanoacrylates), poly(esters), poly(iminocarbonates), poly(amino acids), collagen, gelatin, hydrogel or a blood plasma protein, and copolymers thereof. Preferably, Z is a protein.
Preferably, Z is a protein selected from the group consisting of albumin, transferrin, immunoglobulin.
Preferably, Z is a linear or branched poly( ethylene glycol) with a molecular weight from
2,000 Da to 150,000 Da.
Even more preferred is a prodrug of the present invention, wherein D-H is a GLP-I receptor agonist; L is L1 represented by formula (I) as indicated above; and Z is a hydrogel. Even more preferably, in formula (I) X is N(R4), X1 is C and X3 is O. Even more preferably, L is represented by formula (Ia) as indicated above.
GLP-I is one of the intestinal peptide hormones that are released into the circulatory system after food intake. It augments the postprandial release of insulin, when nutritions (especially carbohydrates) are absorbed and their level postprandially elevated. GLP-I associates with
GLP-I receptor sites located on pancreatic β-cells and elevates endogenous cAMP levels in a dose dependent manner. In isolated rat islets in the presence of above normoglycemic glucose levels, GLP-I stimulates the release of insulin. A therapeutic potential for GLP-I in type 2 diabetes patients was suggested before, owing to the profound efficacy of this insulinotropic peptide to stimulate secretion of insulin when glucose levels are elevated and to cease doing so upon return to normoglycemia. The antidiabetogenic effect of glucagon- like peptide- 1 (7-
36) amide in normal subjects and patients with diabetes mellitus is described e. g. in N. Engl.
J. Med. 326(20): 1316-1322. In vitro studies and animal experiments suggest that GLP-I improves insulin sensitivity and has an anabolic effect on pancreatic β-cells. In humans, GLP-
1 was also reported to suppress glucagon secretion, decelerate gastric empyting, and induce satiety, leading to weight loss if administered for weeks and months.
Exendin-4 is reported to associate with GLP-I receptors located on pancreatic beta-cells with 2.5 times higher affinity than GLP-I. In isolated rat islets and beta-cells in presence of glucose, exendin enhances secretion of insulin in a dose-dependent fashion. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide l-(7-36)-amide receptor of insulin-secreting beta-cells (see J. Biol. Chem. 268(26): 19650-19655). Studies in type 2 diabetic rodents revealed that exendin-4 is 5530-fold more potent than GLP-I in lowering blood glucose levels. Also, the duration of glucose- lowering action after a single administration of exendin-4 is significantly longer compared to GLP-I (see e.g. Diabetes 48(5): 1026-1034). Plasma half-life of exendin-4 in humans was described to be only 26 minutes. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers (see e.g. Am. J. Physiol. Endocrinol. Metab. 281(1):E155-61).
Accordingly in an even more preferred embodiment the GLP-I receptor agonist is Exendin-4.
Hydrogels to be used are known in the art. Suitable hydrogels may be used which are described in WO-A 2006/003014. Accordingly, a hydrogel may be defined as a three- dimensional, hydrophilic or amphiphilic polymeric network capable of taking up large quantities of water. The networks are composed of homopolymers or copolymers, are insoluble due to the presence of covalent chemical or physical (ionic, hydrophobic interactions, entanglements) crosslinks. The crosslinks provide the network structure and physical integrity. Hydrogels exhibit a thermodynamic compatibility with water which allow them to swell in aqueous media. The chains of the network are connected in such a fashion that pores exist and that a substantial fraction of these pores are of dimensions between 1 nm and 1000 nm.
Another object of the present invention is a pharmaceutical composition comprising a prodrug of the present invention or a pharmaceutical salt thereof together with a pharmaceutically acceptable excipient.
Yet another object of the present invention is a prodrug of the present invention or a pharmaceutical composition of the present invention for use as a medicament.
Yet another object of the present invention is a method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions comprising administering to said patient a therapeutically effective amount of a prodrug of the present invention or a pharmaceutical composition of the present invention or a pharmaceutically acceptable salt thereof.
Another object of the present invention is a prodrug precursor of formula Act-L, wherein L has the meaning as indicated above and Act is a leaving group. Preferably, Act is chloride, bromide, fluoride, nitrophenoxy, imidazolyl, N- hydroxysuccinimidyl, N-hydroxybenzotriazolyl, N-hydroxyazobenzotriazo IyI, pentafluorophenoxy, 2-thiooxo-thiazolidinyl, or N-hydroxysulfosuccinimidyl.
Examples
Materials and Methods
Materials: Side chain protected Exendin-4 (J. Eng et al, J. Biol.Chem. 1992, 267, 11, 7402- 7405) on Rink amide resin, side chain protected BNP-32a (human, CyslO and Cys26 exchanged for Ala) on chlorotrityl resin, side chain protected BNP-32b with ivDde side-chain protecting group on Lysl4 (human, CyslO and Cys26 exchanged for Ala) on chlorotrityl resin, and side chain protected human growth hormone releasing factor fragment 1-29 amide (GRF(I -29)) on Rink amide (each synthesized by Fmoc-strategy) were obtained from Peptide Specialty Laboratories GmbH, Heidelberg, Germany. Standard side chain protecting groups were used except for Lys27 of Exendin-4 and Lys21 of GRF(l-29) where Mmt side-chain protecting groups were used.
4OkDa methoxy poly(ethylene glycol) maleimido-propionamide (PEG40kDa-maleimide) was obtained from Chirotech Technology Ltd, Cambridge, UK.
2-Chlorotrityl chloride resin, Sieber amide resin and amino acids were from Merck Biosciences GmbH, Schwalbach/Ts, Germany, if not stated otherwise. Fmoc-D- Homocysteine(Trt)-OH and S-Trityl-3-mercaptopropionic acid (Trt-MPA) were obtained from Bachem AG, Bubendorf, Switzerland. O-(N-Fmoc-2-aminoethyl)-O'-(2-carboxyethyl)- undecaethyleneglycol (Fmoc-Pop-OH) was obtained from Polypure AS, Oslo, Norway.
Fmoc-4-(2-aminoethyl)-l-carboxymethyl-piperazine (Fmoc-Acp-OH) was purchased from NeoMPS SA, Strasbourg, France. cis-Cyclohexane-l,2-dicarboxylic anhydride was obtained from Alfa Aesar GmbH & Co KG, Karlsruhe, Germany.
All other chemicals were from Sigma- ALDRICH Chemie GmbH, Taufkirchen, Germany.
Solid phase synthesis was performed on 2-Chlorotrityl chloride resin with a loading of 1.3 mmol/g or Sieber amide resin with a loading of 0.55 mmol/g. Syringes equipped with polypropylene frits were used as reaction vessels. Loading of the first amino acid to resins was performed according to manufacturer's instructions.
Fmoc deprotection: For Fmoc protecting-group removal, the resin was agitated with 2/2/96 (v/v/v) piperidine/DBU/DMF (two times, 10 min each) and washed with DMF (ten times).
ivDde deprotection:
For ivDde protecting-group removal, the resin was agitated with 98/2 (v/v) DMF/hydrazine hydrate (3 times, 10 min each) and washed with DMF (ten times).
Boc protection:
The N-terminus of a peptide was boc-protected by agitating the resin with 30 eq (boc)2θ and
60 eq pyridine in DCM. After 1 h the resin was washed with DCM (10 times).
Standard coupling condition for acids:
Coupling of acids (aliphatic acids, Fmoc-amino acids) to free amino groups on resin was achieved by agitating resin with 3 eq of acid, 3 eq PyBOP and 6 eq DIEA in relation to free amino groups on resin (calculated based on theoretical loading of the resin) in DMF at room temperature. After 1 hour resin was washed with DMF (10 times). 3-maleimido propionic acid coupling:
Coupling of 3-maleimido propionic acid to free amino groups on resin was achieved by agitating resin with 2 eq of acid, 2 eq DIC and 2 eq HOBt in relation to free amino groups in DMF at room temperature. After 30 min, resin was washed with DMF (10 times).
Standard protocol for synthesis of ureas on resin:
Synthesis of ureas on resin was achieved by agitating resin with 2.5 eq of bis(pentafluorophenyl) carbonate, 5 eq DIEA, and 0.25 eq DMAP in relation to free amino groups in DCM/ACN 1/1 at room temperature. After 15 min resin was washed with DMF (10 times). 5 eq of amine was dissolved in DMF. Mixture was added to resin and agitated for 60 min at room temperature. Resin was washed with DMF (10 times).
Cleavage protocol for Sieber amide resin: Upon completed synthesis, the resin was washed with DCM (10 times), dried in vacuo and treated repeatedly (five times a 15 minutes) with 97/2/1 (v/v) DCM/TES/TFA. Eluates were combined, volatiles were removed under a nitrogen stream and product was purified by RP- HPLC. HPLC fractions containing product were combined and lyophilized.
Cleavage protocol for 2-chlorotrityl chloride resin:
Upon completed synthesis, the resin was washed with DCM, dried in vacuo and treated two times for 30 minutes with 6/4 (v/v) DCM/HFIP. Eluates were combined, volatiles were removed under a nitrogen stream and product was purified by RP-HPLC. HPLC fractions containing product were combined and lyophilized.
Cleavage protocol for Rink amide resin:
Upon completed synthesis, the resin was washed with DCM, dried in vacuo and treated with 2 ml of TFA cleavage cocktail (TFA/TES/Water/DTT 95/2/2/1) per 100 mg resin for 60 min at room temperature. Volatiles were removed under a nitrogen stream. Unpolar side products and protecting groups were removed by precipitating peptide from diethyl ether. Precipitate was dried in vacuo and dissolved in ACN/water 1/1 and purified by RP-HPLC.
Amine containing products obtained as TFA salts were converted to the corresponding HCl salts using ion exchange resin (Discovery DSC-SAX, Supelco, USA). This step was performed in case the residual TFA was expected to interfere with e.g. a subsequent coupling reactions.
RP-HPLC purification:
RP-HPLC was done on a 100x20 or a 100x40 mm Cl 8 ReproSil-Pur 300 ODS-3 5μ column (Dr. Maisch, Ammerbuch, Germany) connected to a Waters 600 HPLC System and Waters
2487 Absorbance detector. Linear gradients of solution A (0.1% TFA in H2O) and solution B
(0.1% TFA in acetonitrile) were used. HPLC fractions containing product were lyophilized.
Analytics: Electrospray ionization mass spectrometry (ESI-MS) was performed on a Waters ZQ 4000 ESI instrument and spectra were, if necessary, interpreted by Waters software MaxEnt.
Size exclusion chromatography (SEC) was performed using an Amersham Bioscience AEKTAbasic system equipped with a Superdex200 10/300 column (Amersham Bioscience/GE Healthcare), if not stated otherwise. 10 rnM sodium phosphate, 140 mM NaCl, pH 7.4, 3 mM EDTA was used as mobile phase
For Cation Exchange Chromatography, an Amersham Bioscience AEKTAbasic system was equipped with a Source 15S filled HR16/10 column (Amersham Bioscience/GE Healthcare).
Desalting was performed using an Amersham Bioscience AEKTAbasic system equipped with a HiPrep 26/10 Desalting column and 0.1% acetic acid in water as mobile phase.
In vitro linker hydrolysis and release of drug: Compounds were dissolved in buffer A (10 mM sodium phosphate, 140 mM NaCl, pH 7.4, 3 mM EDTA) or buffer B (0.1 M Acetat 3 mM EDTA, pH 4.0), and solution was filtered through a 0.2 μm filter and incubated at 37 0C. Samples were taken at time intervals and analyzed by RP-HPLC at 215 nm and ESI-MS. UV- signals correlating to liberated drug molecule were integrated and plotted against incubation time. In case of identical retention times of prodrug and drug, ratio of mass signals was used to determine release kinetics.
For hydrogel conjugates, compounds were suspended in buffer A and incubated at 37°C. Samples were taken after centrifugation of the suspension and analyzed by RP-HPLC at 215 nm. UV-signals correlating to liberated drug molecule were integrated and plotted against incubation time.
Curve-fitting software was applied to estimate the corresponding halftime of release.
Example 1
Synthesis of fatty acid carrier (1)
Figure imgf000031_0001
1 was synthesized on sieber amide resin (477 mg, 0.262 mmol) by coupling of Fmoc-
Lys(ivDde)-OH, fmoc deprotection, coupling of dodecanoic acid, ivDde deprotection, coupling of Fmoc-Pop-OH, fmoc deprotection, coupling of 3-maleimido propionic acid, cleavage from resin and purification as depicted above and described in "Materials and
Methods".
Yield: 128 mg (0.119 mmol).
MS: m/z 1101.0 = [M+Na]+ (MW calculated = 1078.4 g/mol).
Example 2
Synthesis of Linker reagent (2)
Figure imgf000031_0002
Linker reagent 2 was synthesized on 3-chlorotrityl chloride resin (300 mg, 0.39 mmol) by loading of resin with Fmoc-Cys(Trt)-OH, fmoc deprotection, and on-resin urea formation using N,N-dimethyl-ethylenediamine as amine, cleavage from resin as depicted above and described in "Materials and Methods". For RP-HPLC separation, 0.01% HCl in water was used as solution A and 0.01% HCl in acetonitrile was used as solution B. Yield: 82 mg of HCl salt (0.16 mmol). MS: m/z 478.2 = [M+H]+ (MW calculated = 477.6 g/mol).
Example 3
Synthesis of Exendin-4 linker intermediate (3)
Figure imgf000032_0001
2 (14 mg, 0.027 mmol), PyBOP (14 mg, 0.027 mmol), and DIEA (17 μl, 0.10 mmol) were dissolved in 0.2 ml of dry DMF. Mixture was added to 22 mg side-chain protected Exendin-4 on-resin (0.1 mmol/g, 2.2 μmol) and agitated for 30 min at room temperature. Resin was washed with DMF (10 times) and DCM (10 times). 3 was cleaved from resin and purified by RP-HPLC as described in "Materials and Methods". Yield: 1.7 mg 3 as TFA salt (0.38 μmol).
MS: m/z 1468.7 = [M+3H]3+ (MW calculated = 4403 g/mol).
Example 4
Synthesis of fatty acid-PEG-linker-Exendin-4 conjugate (4)
Figure imgf000033_0001
3 (1.7 mg, 0.38 μmol) and 1 (0.6 mg, 0.58 μmol) were dissolved in 500 μl of acetonitrile/water 7/3 (v/v). 40 μl of 0.5 M phosphate buffer (pH 7.4) were added and the mixture was incubated at RT for 10 min. Conjugate 4 was purified by RP-HPLC. MS: m/z 1828.7 = [M+3H]3+ (MW calculated = 5480 g/mol).
Example 5
Synthesis of linker intermediate (5a)
Figure imgf000033_0002
5a
Fmoc-Acp-OH • 2 HCl (100 mg, 0.21 mmol) was suspendend in 400 μl DMF/DMSO 1/1 (v/v). S-tritylcysteamine • HCl (75 mg, 0.21 mmol), PyBOP (109 mg, 0.21 mmol) and DIEA (146 μl, 0.86 mmol) were added and mixture was agitated for 60 min at RT. Fmoc group was removed by adding 75 μl piperidine and 25 μl DBU. After 15 min mixture was hydro lyzed and acidified (AcOH) and compound was purified by RP-HPLC. After lyophilization 98 mg (0.14 mmol, double TFA salt) were obtained. MS: m/z 511.6 = [M+Na]+ (MW calculated = 488.7 g/mol).
Synthesis of cis-cyclohexane diacarboxylic acid amoxapine monoamide (5b)
Figure imgf000034_0001
+ enantiomer
Amoxapine (200 mg, 0.64 mmol) and cis-cyclohexane-l,2-dicarboxylic anhydride (108 mg, 0.70 mmol) were dissolved in 700 μl of dry DMF. Pyridine (130 μl, 1.6 mmol) was added and mixture was stirred for 60 min at RT. Mixture was quenched with 2 ml of acetonitrile/acetic acid/water (1/1/1) and purified by RP-HPLC. After lyophilization 344 mg (0.49 mmol, double TFA salt) of 5b were obtained. MS: m/z 468.5 = [M+H]+ (MW calculated = 468.0 g/mol).
Synthesis of linker-amoxapine conjugate (5c)
Figure imgf000034_0002
5b (7 mg, 0.010 mmol) was preactivated by incubating with PyBOP (12.5 mg, 0.024 mmol) and DIEA (5 μl, 0.03 mmol) in 200 μl of dry DMF for 45 min at RT. 5a (20 mg, 0.028 mmol) and DIEA (15 μl, 0.09 mmol) were added and mixture was incubated for further 60 min. Mixture was quenched with 0.5 ml of acetonitrile/acetic acid/water (1/1/1) and purified by RP-HPLC. After lyophilization 3 mg (0.0026 mmol, double TFA salt) of 5c were obtained. MS: m/z 939.3 = [M+H]+ (MW calculated = 938.6 g/mol).
For trityl deprotection, lyophilisate was incubated in 1 ml HFIP and 3 μl TES for 30 min. Mixture was evaporated and thiol was purified by RP-HPLC. After lyophilization 2 mg (2.2 μmol, double TFA salt) of amoxapine- linker conjugate 5c were obtained. MS: m/z 697.1 = [M+H]+ (MW calculated = 696.3 g/mol).
Synthesis of fatty acid-PEG-amoxapine conjugate (5)
Figure imgf000035_0001
Amoxapine- linker conjugate 5c (2 mg, 2.2 μmol) and 1 (3.5 mg, 3.2 μmol) were dissolved in 900 μl of acetonitrile/water 7/3 (v/v). 60 μl of 0.5 M phosphate buffer (pH 7.4) were added and the mixture was incubated at RT for 10 min. 5 was purified by RP-HPLC. MS: m/z 1774.9 = [M+H]+ (MW calculated = 1774.7 g/mol).
Example 6
Synthesis of linker reagent (6)
Figure imgf000035_0002
Fmoc-Asp(tBu)-OH (411 mg, 1 mmol), HOBt (153 mg, 1 mmol), and DIC (160 μl, 1 mmol) were dissolved in 2 ml of DMF and incubated for 10 min at RT. N,N-dimethyl ethylenediamine (160 μl, 1.5 mmol) was added and stirred at RT for 30 min. Acetic acid (300 μl) was added and Fmoc-Asp(tBu)-NH-(CH2)2-N(CH3)2 was purified by RP-HPLC.
Yield: 220 mg (0.46 mmol)
MS Fmoc-Asp(tBu)-NH-(CH2)2-N(CH3)2: m/z 504.6 = [M+Na]+ (MW calculated = 481.6 g/mol).
Fmoc-Asp(tBu)-NH-(CH2)2-N(CH3)2 (220 mg, 0.46 mmol) was dissolved in 3 ml of 98/2
(v/v) TFA/TES. After 30 min the solvent was removed under a nitrogen stream and 6 was purified by RP-HPLC using 0.01% HCl in water as solvent A and 0.01% HCl in acetonitril as solvent B. Yield: 146 mg (0.32 mmol, HCl salt)
MS: m/z 426.5 = [M+H]+ (MW calculated = 425.5 g/mol). Example 7
Synthesis of linker reagents 7a and 7b
Figure imgf000036_0001
7a : R = H
Figure imgf000036_0002
Synthesis of 7a:
Fmoc-Asp(tBu)-OH (300 mg, 0.73 mmol), HOBt (1112 mg, 0.73 mmol), and DIC (117 μl, 0.73 mmol) were dissolved in 2 ml of DMF and incubated for 10 min at RT. Boc- ethylenediamine (230 mg, 1.44 mmol) was added and stirred at RT for 30 min. Acetic acid (300 μl) was added and Fmoc- Asp(tBu)-NH-(CH2)2-NH-boc was purified by RP-HPLC. Yield: 205 mg (0.37 mmol) MS intermediate: m/z 576.6 = [M+Na]+ (MW calculated = 553.7 g/mol).
Fmoc-Asp(tBu)-NH-(CH2)2-NH-boc (205 mg, 0.37 mmol) was dissolved in 3 ml of 98/2 (v/v) TFA/TES. After 30 min the solvent was removed under a nitrogen stream and Fmoc-Asp(H)- NH-(CH2)2-NH2 was purified by RP-HPLC. Yield: 140 mg (0.27 mmol, TFA salt) MS intermediate: m/z 398.8 = [M+H]+ (MW calculated = 397.4 g/mol).
Fmoc-Asp(H)-NH-(CH2)2-NH2 (140 mg, 0.27 mmol, TFA salt) was dissolved in 1 ml of DMF and DIEA (140 μl, 0.81 mmol) and boc2θ (100 mg, 0.46 mmol) added. The solution was stirred at RT for 15 min and then acidified with acetic acid (300 μl). 7a was purified by RP- HPLC. Yield 7a: 120 mg (0.24 mmol)
MS 7a: m/z 520.5 = [M+Na]+ (MW calculated = 497.6 g/mol). 7b was synthesized as described above except for the use of H2N-(CH2)2-N(CH3)-boc instead of boc-ethylenediamine as amine in the first step. Yield 7b: 115 mg
MS 7b: m/z 534.5 = [M+Na]+ (MW calculated = 511.6 g/mol).
Example 8
Synthesis of Exendin-linker conjugates 8a, 8b and 8c
Figure imgf000037_0001
8a: R1 = H, R2 = H 8b: R1 = H, R2 = CH3 8c: R1 = CH3, R2 = CH3 Synthesis of 8a:
7a (30 mg, 60 μmol), HOBt (9 mg, 60 μmol), DIEA (12 μl, 70 μmol), and DIC (10 μl, 63 μmol) were dissolved in 200 μl of DMF and immediately added to side-chain protected
Exendin-4 on resin (40 mg, 4 μmol) and incubated for 1 h at room temperature. Resin was washed ten times with DMF and then incubated for 5 min with 500 μl of 1/1/2 acetic anhydride/pyridine/DMF. Resin was washed 10 times with DMF and fmoc group was removed. Trt-mercaptopropionic acid was coupled and 8a was cleaved from resin and purified by RP-HPLC.
Yield: 3.6 mg
MS 8a: m/z 1108.5 = [M+4H]4+; 1477.8 = [M+3H]3+ (MW calculated = 4432 g/mol).
8b was synthesized as described above for 8a except for the use of 7b instead of 7a.
Yield: 3.5 mg
MS 8b: m/z 1112.5 = [M+4H]4+; 1482.5 = [M+3H]3+ (MW calculated = 4446 g/mol).
8c was synthesized as described above for 8a except for the use of 6 instead of 7a. Yield: 3.2 mg
MS 8c: m/z 1116.2 = [M+4H]4+; 1487.8 = [M+3H]3+ (MW calculated = 4460 g/mol).
Example 9
Synthesis of PEG40kDa-linker-Exendin conjugates 9a, 9b, and 9c
Figure imgf000038_0001
9a: R1 = H, R2 = H
9b: R1 = H, R2 = CH3
9c: R1 = CH3, R2 = CH3
Synthesis of 9a: 8a (3.6 mg) was dissolved in 300 μl 2/1 water/acetonitrile and 50 mg PEG40kDa-maleimide was added. 100 μl 0.25 M sodium phosphate buffer pH 7 were added and after 5 min the solution was acidfϊed with 50 μl acetic acid.
9a was purified by ion exchange chromatography using 10 mM sodium citrate pH 3 as solvent A and 10 mM sodium citrate pH 3 and 1 M NaCl as solvent B and a step-gradient (0 to 40% B). Fractions containing 9a were desalted and lyophilized:
Yield: 14 mg
9b was synthesized as described above except for the use of 8b. Yield: 15 mg 9c was synthesized as described above except for the use of 8c. Yield: 13 mg
Example 10
Synthesis of fatty acid-linker-Exendin conjugate 10
Figure imgf000039_0001
8c (1 mg) was dissolved in 100 μl 1/1 acetonitrile/water and 1 (1 mg) in 100 μl of 3/1 acetonitrile/water was added. 100 μl of 0.25 M sodium phosphate buffer was added, the reaction was stirred for 5 min, after which 10 was purified by RP-HPLC. Yield: 1.3 mg MS 10: m/z 1385.9 = [M+4H]4+; 1846.3 = [M+3H]3+ (MW calculated = 5528.3 g/mol).
Example 11
Synthesis of NHS-activated linker reagent 11
Figure imgf000039_0002
7b (20 mg, 40 μmol), N^'-dicyclohexylcarbodiimide (10 mg, 48 μmol), and NHS (8 mg, 70 μmol) were dissolved in 300 μl of dry DCM and stirred at RT for 1 h. Solvent was removed under a nitrogen stream and 11 was purified by RP-HPLC and lyophilized.
Yield: 22 mg (36 μmol)
MS: m/z 631.5 = [M+Na]+ (MW calculated = 608.7 g/mol). Example 12
Synthesis of linker-Exendin(Fluorescein) conjugate (12a) and linker-GRF(l- 29)(Fluorescein) conjugate (12b)
Figure imgf000040_0001
12a: R = Exendin(εK27-fluorescein) 12b: R = GRF(I -29)(εK21 -fluorescein)
6 (60 mg, 130 μmol HCl salt), HOBt (20 mg, 130 μmol), DIEA (40 μl, 230 μmol), and DIC (20 μl, 126 μmol) were dissolved in 700 μl of DMF and immediately added to side-chain protected Exendin-4 on resin (120 mg, 12 μmol) and incubated for 1 h at room temperature. Resin was washed ten times with DMF and then incubated for 5 min with 1 ml of 1/1/2 (v/v/v) acetic anhydride/pyridine/DMF. Resin was washed ten times with DMF and fmoc group was removed. Trt-mercaptopropionic acid was coupled according to standard coupling method and resin was washed five times with DMF and ten times with DCM. Mmt protecting group of Lys27 was removed by incubation of resin five times in 2 ml of 9/1 (v/v) DCM/HFIP for 5 min. Resin was washed five times with DCM and five times with DMF and 5,6-carboxy-flourescein-NHS ester (20 mg, 42 μmol) and DIEA (20 μl, 115 μl) in 300 μl DMF were added to resin and incubated for 30 min. 12a was cleaved from resin and purified by RP-HPLC Yield: 12 mg
MS 12a: m/z 1205.9 = [M+4H]4+; 1607.0 = [M+3H]3+ (MW calculated = 4818.3 g/mol). 12b was synthesized as described for 12a except for the use of GRF(l-29) on resin (120mg, 12 μmol). Yield: l l mg MS 12b: m/z 998.6 = [M+4H]4+; 1330.5 = [M+3H]3+ (MW calculated = 3989.6 g/mol). Synthesis of mercaptopropionyl-Exendin(Fluorescein) (12c) and mercaptopropionyl- GRF(l-29)(Fluorescein) (12d)
H
HS N-R
O
12c: R = Exendin(εK27-fluorescein) 12d: R = GRF(I -29)(εK21 -fluorescein)
Trt-mercaptopropionic acid was coupled according to standard coupling method to side-chain protected Exendin-4 on resin (120 mg, 12 μmol). Mmt protecting group removal of Lys27 and
5,6-carboxy-flourescein-NHS ester coupling was performed as described for 12a. 12c was cleaved from resin and purified by RP-HPLC Yield: 13 mg
MS 12c: m/z 1545.6 = [M+3H]3+ (MW calculated = 4633 g/mol).
12d was synthesized as described for 12c except for the use of GRF(I -29) on resin (120mg,
12 μmol).
Yield: l l mg MS 12d: m/z 1269.1 = [M+3H]3+ (MW calculated = 3804.3 g/mol).
Example 13
Synthesis of reversible PEG40kDa-linker-Exendin(Fluorescein) conjugate (13a) And reversible PEG40kDa-linker-GRF(l-29)(Fluorescein) conjugate (13b)
Figure imgf000041_0001
13a: R = Exendin(εK27-fluorescein) 13b: R = GRF(I -29)(εK21 -fluorescein) 12a (12 mg) was dissolved in 500 μl of 1/1 acetonitrile/water and 120 mg PEG40kDa- maleimide in 1 ml of 1/1 acetonitrile/water was added. 300 μl of 0.25 M sodium phosphate buffer pH 7.0 were added and solution was acidified after 10 min with 300 μl acetic acid. 13a was purified by cation exchange chromatography, desalted, and then lyophilized. Yield: 51 mg
13b was synthesized as described for 13a except for the use of 12b instead of 12a. Yield: 46 mg
Synthesis of permanent PEG40kDa- Exendin(Fluorescein) conjugate (13c) and permanent PEG40kDa-GRF(l-29)(Fluorescein) conjugate (13d)
Figure imgf000042_0001
13c: R = Exendin(εK27-fluorescein) 13d: R = GRF(I -29)(εK21 -fluorescein)
13c was synthesized as described for 13a except for the use of 12c instead of 12a. Yield: 55 mg
13d was synthesized as described for 13a except for the use of 12d instead of 12a. Yield: 45 mg
Example 14
Synthesis of linker-GRF(l-29) conjugate 14
Figure imgf000042_0002
14 was synthesized as described for 8c except for the use of side-chain protected GRF(I -29) resin.
Yield: 10 mg
MS 14: m/z 908.2 = [M+4H]4+; 1211.2 = [M+3H]3+ (MW calculated = 3631.3 g/mol).
Example 15
Synthesis of PEG40kDa-linker-GRF(l-29) conjugate (15)
Figure imgf000043_0001
15 was synthesized as described for 9c except for the use of 14 and 10 rnM sodium citrate pH 4 as solvent A and 10 rnM sodium citrate pH 4 and 1 M sodium chloride as solvent B for cation exchange chromatography. Yield: 11 mg
Example 16
Synthesis of linker intermediate 16
H
Figure imgf000043_0002
N,N-dimethylethylenediamine (198 μL, 1.8 mmol) and NaCNBH3 (58 mg, 0.9 mmol) were dissolved in methanol (5 mL) and brought to pH 5.5 by addition of AcOH (250 μL). A suspension of 2,4,6, -trimethoxybenzaldehyde (294 mg, 1.5 mmol) in EtOH (5 mL) was added and the reaction was stirred at RT for 1 h. 5 N HCl (0.5 mL) was added and the mixture was stirred for further 12 h. The solvent was removed under reduced pressure; the residue was dissolved in sat. NaHCO3 and extracted 3x with DCM. The combined organic phases were dried over NaSO4 and the solvent was evaporated under reduced pressure. Yield: 303 mg (1.13 mmol) MS: m/z 269.3 = [M+H]+ (MW calculated = 268.4 g/mol)
Example 17
Synthesis of linker 17a and 17b
Figure imgf000044_0001
Synthesis of 17a:
Fmoc-Asp(OtBu)-OH (322 mg, 0.78 mmol), Tmob-protected diamine 16 (150 mg, 0.56 mmol), HATU (255 mg, 0.67 mmol) and DIEA (290 μL, 1.68 mmol) were dissolved in DMF (1.5 mL). The mixture was stirred for 30 min, acidified with AcOH and purified by RP-
HPLC.
Yield: 463 mg (5.97 mmoLTFA salt, ca. 90% pure)
MS FmOC-ASp(OtBu)-N(TMOB)CH2CH2N(CHs)2 : m/z 662.5 = [M+H]+ (MW calculated =
661.8 g/mol)
Fmoc-Asp(OtBu)-N(Tmob)CH2CH2N(CH3)2 (225 mg, 0.29 mmol) was dissolved in a solution of piperidine (50 μL) and DBU (15 μL) in DMF (1.5 mL). The mixture was stirred at
RT for 1.5 h. AcOH was added and H-Asp(OtBu)-N(TMOB)CH2CH2N(CH3)2 was purified by RP-HPLC. Yield: 114 mg (0.21 mmol, TFA salt)
MS H-ASp(OtBu)-N(TmOb)CH2CH2N(CHs)2: m/z 462.4 = [M+Na]+ (MW calculated = 439.6 g/mol)
The TFA salt OfH-ASp(OtBu)-N(TmOb)CH2CH2N(CHs)2 (114 mg, 0.21 mmol) was dissolved in sat. NaHCO3 (10 mL) and extracted 3x with DCM (3x 10 mL). The combined organic layers were dried over NaSO4 and the solvent was removed under reduced pressure. The residue was dissolved in DMF (1.0 mL), 6-tritylmercaptohexanoic acid (121 mg, 0.31 mmol), HATU (118 mg, 0.31 mmol) and DIEA (108 μL, 0.62 mmol) were added. The mixture was stirred for 30 min. AcOH was added (200 μL) and TrtS(CH2)5CONH-Asp(OtBu)- N(TmOb)CH2CH2N(CHs)2 was purified by RP-HPLC. Yield: 95 mg (0.10 mmol, TFA salt)
MS TrtS(CH2)5CONH- ASp(OtBu)-N(TmOb)CH2CH2N(CHs)2: m/z 812.64 = [M+H]+ (MW calculated = 812.1 g/mol)
TrtS(CH2)5CONH- ASp(OtBu)-N(TmOb)CH2CH2N(CHs)2 (95 mg, 0.10 mmol) was dissolved in a 3:1 mixture of MeOH/H2O (1.0 mL), LiOH (7.4 mg, 0.31 mmol) was added and the mixture was stirred for 5 h at 600C. AcOH was added (100 μL) and 17a was purified by RP- HPLC.
Yield: 64 mg (0.07 mmol, TFA salt)
MS 17a: m/z 756.5 = [M+H]+ (MW calculated = 756.0 g/mol)
17b was synthesized as described above except for the use of Fmoc-NMe-Asp(OtBu)-OH instead of Fmoc-Asp(OtBu)-OH in the first step. Yield 17b: 16 mg (18 μmol, TFA salt) MS 17b: m/z 770.5 = [M+H]+ (MW calculated = 770.0 g/mol)
Example 18
Synthesis of linker-BNP conjugates 18a and 18b
Figure imgf000045_0001
Synthesis of 18a:
17a (8.0 mg, 0.01 mmol), PyBOP (5.2 mg, 10 μmol) and DIEA (7 μL, 40 μmol) were dissolved in DMF (400 μL) and immediately added to resin bound, side chain protected BNP- 32a (50 mg, 5 μmol). After incubation for 2 h at RT, the resin was washed with 1Ox DMF, 1Ox DCM and dried in vacuo. The product was cleaved from the resin and purified by RP- HPLC. Yield: 10.6 mg
MS 18a: m/z 930.4 = [M+4H]4+; 1240.1 = [M+3H]3+ (MW calculated = 3717.2 g/mol)
18b was synthesized as described above except for the use of 17b instead of 17a. Yield: 4.7 mg
MS 18b: m/z 933.9 = [M+4H]4+; 1244.7 = [M+3H]3+ (MW calculated = 3731.0 g/mol)
Example 19
Synthesis of PEG40kDa-linker-BNP conjugates 19a and 19b
Figure imgf000046_0001
18a (5.2 mg) was dissolved in 1 :1 H2O/acetonitrile containing 0.1 % TFA (200 μL). A solution of PEG40kDa-maleimide (70 mg) in 1 : 1 F^O/acetonitrile (1.5 mL) and phosphate buffer (30 μL, pH 7.4, 0.5 M) was added. The solution was incubated at RT, after 5 min AcOH (30 μL) was added. 19a was purified by cation exchange chromatography, desalted, and lyophilized. Yield: 19.2 mg
19b was synthesized as described for 19a except for the use of 18b instead of 18a.
Example 20
Synthesis of linker 20
Figure imgf000046_0002
20 Fmoc-Asp(OH)OtBu (100 mg, 0.24 mmol), H2N-(CH2)2-N(CH3)-boc (36 μL, 0.20 mmol), HATU (92 mg, 0.24 mmol) and DIEA (105 μL, 0.60 mmol) were dissolved in 1 mL DMF. The mixture was stirred for 1 h at RT, acidified with AcOH (100 μL) and purified by HPLC. Yield: 91 mg (0.13 mmol) MS Fmoc-Asp(NH(CH2)2N(CH3)-boc)OtBu: 590.3 = [M+Na]+ (MW calculated = 567.7 g/mol)
Fmoc-Asp(NH(CH2)2N(CH3)-boc)OtBu (91 mg, 0.13 mmol) was dissolved in DMF (1.0 mL), piperidine (50 μL) and DBU (15 μL) were added and the mixture was stirred for 45 min at RT. AcOH (100 μL ) was added and NH2-Asp(NH(CH2)2N(CH3)-boc)OtBu was purified by RP-HPLC.
Yield: 39 mg (0.09 mmol, TFA salt)
MS NH2-Asp(NH(CH2)2N(CH3)-boc)OtBu: m/z 368.1 = [M+Na]+ (MW calculated = 345.4 g/mol)
NH2-Asp(NH(CH2)2N(CH3)-boc)OtBu (36 mg, 0.09 mmol) was dissolved in DMF (0.5 mL), 6-tritylmercaptohexanoic acid (55 mg, 0.14 mmol), HATU (53 mg, 0.14 mmol) and DIEA (49 μL, 0.28 mmol) were added. The mixture was stirred for 45 min. AcOH was added (100 μL) and TrtS(CH2)5CONH-Asp(NH(CH2)2N(CH3)-boc)OtBu was purified by RP-HPLC. Yield: 41 mg (0.06 mmol)
MS TrtS(CH2)5CONH-Asp(NH(CH2)2N(CH3)-boc)OtBu: m/z 740.6 = [M+Na]+ (MW calculated = 718.0 g/mol)
TrtS(CH2)5CONH-Asp(NH(CH2)2N(CH3)-boc)OtBu (41 mg, 0.06 mmol) was dissolved in 1 :1 dioxane/H2O (1.0 mL), LiOH (4.1 mg, 0.17 mmol) was added and the mixture was stirred at 600C for Ih. AcOH (50 μL) was added and 20 was purified by RP-HPLC. Yield: 31 mg (0.05 mmol) MS 20: m/z 684.5 = [M+Na]+ (MW calculated = 661.9 g/mol)
Example 21
Synthesis of linker-exendin conjugate 21
Figure imgf000048_0001
Resin bound, side chain protected exendin (50 mg, 5 μmol) with a Mmt protecting-group on Lys27 was first boc-protected at the N-terminus (see Materials and Methods) and then incubated five times (5 min) with 2 rnL of 9/1 (v/v) DCM/HFIP to remove the Mmt protecting group from Lys27. 20 (6.6 mg, 10 μmol), PyBOP (5.2 mg, 10 μmol) and DIEA (7 μL, 40 μmol) were dissolved in DMF (400 μL) and immediately added to the resin. Incubation for 3 h at RT, the resin was washed with 1Ox DMF, 10x DCM and dried in vacuo. The product was cleaved from the resin and purified by RP-HPLC. Yield: 2.4 mg MS 21: m/z 1497.2 = [M+3H]3+ (MW calculated = 4488.0 g/mol)
Example 22
Synthesis of fatty acid-linker-Exendin conjugate 22
Figure imgf000048_0002
22
21 (2.6 mg) was dissolved in 200 μl 1/1 acetonitrile/water and 1 (0.8 mg) in 400 μl of 7/3 acetonitrile/water was added. 100 μl of 0.25 M sodium phosphate buffer was added, the reaction was stirred for 5 min after which 22 was purified by RP-HPLC. Yield: 2.4 mg MS 22: m/z 1388.3 = [M+4H]4+; 1857.1 = [M+3H]3+ (MW calculated = 5566.4 g/mol).
Example 23
Synthesis of precursor 23 OH
Figure imgf000049_0001
6-Tritylmercaptohexanoic acid (200 mg, 0.51 mmol), (PIpO)2CO (202 mg, 0.51 mmol) and collidine (340μL, 2.65 mmol) were dissolved in DMSO (1 mL) and stirred for 30 min at RT. The mixture was added to a solution of Fmoc-Lys-OH (170 mg, 0.46 mmol) in H2O/pyridine/tBuOH (3:3:1, 6 mL). The reaction was heated at 600C for 2h, diluted with EtOAc, extracted 2x with 0.1M H2SO4, 2x with brine and dried over Na2SO4. The solvent was evaporated under reduced pressure and the residue was purified by RP-HPLC. Yield: 109 mg
MS 23: m/z 741.3 [M+H]+ (MW calculated = 741.0 g/mol)
Example 24
Synthesis of linker 24a-24c
Figure imgf000049_0002
24a: R1 = H, R2 = boc 24b: R1 = Me, R2 = boc 24c: R1 = R2 = Me
23 (186 mg, 0.25 mmol) and DIEA (160 μL, 0.92 mmol) were dissolved in DCM (2 mL), added to 2-chlorotrityl chloride resin (312 mg, 1.3 mmol/g) and agitated for 45 min at RT. MeOH (0.6 mL) was added and the resin was incubated for another 15 min. The resin was washed with DCM (1Ox) and DMF (1Ox). Fmoc-deprotection and urea formation was achieved according to general procedures (see Materials and Methods) by reaction with N- boc-ethylenediamine (57 μL, 0.34 mmol), the product was cleaved from the resin and purified by RP-HPLC. Yield: 14 mg
MS 24a: m/z 705.4 [M+H]+, 727.3 [M+Na]+ (MW calculated = 704.9 g/mol)
24b was synthesized as described for 24a except for the use of N-boc-N- methylethylenediamine instead of instead of N-boc-ethylenediamine. Yield: 21 mg MS 24b: m/z 719.3 [M+H]+, 741.4 [M+Na]+ (MW calculated = 719.0 g/mol)
24c was synthesized as described for 24a except for the use of N,N-dimethylethylenediamine instead of N-boc-ethylenediamine. Yield: 10 mg MS 24c: m/z 633.2 [M+H]+ (MW calculated = 632.9 g/mol)
Example 25
Synthesis of exendin-linker conjugates 25a-25c
Figure imgf000050_0001
24a (7.0 mg, 0.01 mmol), PyBOP (5.2 mg, 10 μmol) and DIEA (7 μL, 40 μmol) were dissolved in DMF (250 μL), immediately added to resin bound, side chain protected exendin (50 mg, 5 μmol) and incubated for 2 h at RT. The resin was washed with DMF (1Ox), DCM (1Ox) and dried in vacuo. The product was cleaved from the resin and purified by RP-HPLC. Yield: 1.6 mg MS 25a: m/z 1511.8 = [M+3H]3+ (MW calculated = 4530.8 g/mol)
25b was synthesized as described for 25a except for the use of 24b instead of 24a. Yield: 4.3 mg MS 25b: m/z 1516.3 = [M+3H]3+ (MW calculated = 4544.8 g/mol)
25c was synthesized as described for 25a except for the use of 24c instead of 24a. Yield: 1.3 mg
MS 25c: m/z 1520.4 = [M+3H η]3'++ (MW calculated = 4558.8 g/mol)
Example 26
Synthesis of fatty acid-linker conjugates 26a-26c
Figure imgf000051_0001
25a (1.6 mg) was dissolved in 200 μl 1/1 acetonitrile/water and 1 (0.11 mg) in 200 μl of 7/3 acetonitrile/water was added. 30 μl of 0.25 M sodium phosphate buffer was added, the reaction was stirred for 5 min, after which 26a was purified by RP-HPLC. MS 26a: m/z 1870.0 = [M+3H]3+ (MW calculated = 5609.2 g/mol).
26b was synthesized as described for 26a except for the use of 25b instead of 25a. MS 26b: m/z 1875.9 = [M+3H]3+, 1406.7 = [M+4H]4+ (MW calculated = 5623.2 g/mol)
26c was synthesized as described for 26a except for the use of 25c instead of 25a.
MS 26c: m/z 1879.4 = [M+3H]3+, 1410.5 = [M+4H]4+ (MW calculated = 5637.2 g/mol)
Example 27
Synthesis of 20KDa-PEG-linker-exendin conjugates 27a-27c
H
Figure imgf000051_0002
25a (2.0 mg) was dissolved in 1 :1 H20/MeCN containing 0.1 % TFA (200 μl). A solution of PEG40KDa-maleimide (18 mg) in 1:1 H2O/MeCN (1 ml) and phosphate buffer (15 μl, pH 7.4, 0.5 M) was added. The solution was incubated at RT, after 5 min AcOH (20 μl) was added and 27a was purified by cation exchange chromatography, desalted and lyophilized.
27b was synthesized as described for 27a except for the use of 25b instead of 25a.
27c was synthesized as described for 27a except for the use of 25c instead of 25a.
Example 28
Synthesis of linker 28:
Figure imgf000052_0001
6-Bromohexanoyl chloride (46 μl, 0.31 mmol) was dissolved in 0.2 ml CH2Cl2 and added to a solution Of H2N-CH2-CH2-STiI (100 mg, 0.28 mmol), DIEA (97 μl, 0.56 mmol) in CH2Cl2 (0.8 ml). The mixture was stirred for 2 h at RT. The reaction mixture was acidified with AcOH (50 μl) and the solvent was removed in vacuo. The residue was purified on silica gel (heptane/EtOAc = 1 :1) to obtain Br-(CH2)5-CONH-(CH2)2-STrt. Yield: 137 mg (0.276 mmol, 98 %)
MS Br-(CH2)5-CONH-(CH2)2-STrt: 518.9 = [M+Na]+, (MW calculated = 496.5 g/mol)
JV-Boc-ethylenediamine (81 μl, 0.51 mmol) was added to a solution of Br-(CH2)s-CONH-
(CH2)2-STrt (230 mg, 0.46 mmol) and Na2CO3 (196 mg, 1.85 mmol) in DMF (0.8 ml). The reaction mixture was stirred for 1O h at 70 0C. After cooling to RT the mixture was diluted with 4 ml (MeCN/H2O = 25:75, with 0.1 % TFA) and purified by RP-HPLC to get Boc-NH-
(CH2)2-NH-(CH2)5-CONH-(CH2)2-STrt.
Yield: 189 mg (0.27 mmol, 59 %, TFA-salt)
MS Boc-NH-(CH2)2-NH-(CH2)5-CONH-(CH2)2-STrt: 576.5 = [M+H]+, (MW calculated = 575.5 g/mol) Boc-NH-(CH2)2-NH-(CH2)5-CONH-(CH2)2-STrt (189 mg, 0.27 mmol) and HCHO (35 % aqueous, 113 μl) were dissolved in MeCN (1.5 ml) and NaCNBH3 (34 mg, 0.54 mmol) was added. The reaction mixture was stirred for 5 h at RT. After completion of the reaction (MS) the solution was diluted with H2O (5 ml) and extracted with CH2Cl2 (3 x 5 ml). The combined organic layers were dried over MgSO4, filtered and the solvent was removed in vacuo. The residue was purified by RP-HPLC to get Boc-NH-(CH2)2-N(CH3)-(CH2)5-CONH-(CH2)2- STrt.
Yield: 62.8 mg (0.11 mmol, 39 %)
MS Boc-NH-(CH2)2-N(CH3)-(CH2)5-CONH-(CH2)2-STrt: 590.6 = [M+H]+, (MW calculated = 589.0 g/mol)
Boc-NH-(CH2)2-N(CH3)-(CH2)5-CONH-(CH2)2-STrt (62.8 mg, 0.11 mmol) was dissolved in
THF (6 ml) and HCl in dioxane (130 μl, 4 M solution) was added. The reaction mixture was stirred for 12 h at RT. 200 μl HCl in dioxane was added and the solvent was removed in vacuo. The residue was purified by RP-HPLC to give H2N-(CH2)2-N(CH3)-(CH2)5-CONH-
(CH2)2-STrt and not consumed starting material Boc-NH-(CH2)2-N(CH3)-(CH2)5-CONH-
(CH2)2-STrt.
Yield: 32.8 mg (0.062 mmol, 44 %, HCl-salt) 28 and 14.7 mg (0.025 mmol, 23 %, TFA-salt) starting material MS 28: 490.5 = [M+H]+, (MW calculated = 489.0 g/mol)
Example 29
General procedure for the synthesis carboxylic acid substituted BNP precursors 29a and 29b
Figure imgf000053_0001
Cώ-cyclohexane-l,2-dicarboxylic anhydride (231 mg, 1.5 mmol) and pyridine (271 μl, 2 mmol) were dissolved in DCM (2 ml) and added to resin bound, side chain protected BNP- 32a (300 mg). Incubation for 1 h at RT, washed with 1O x DCM and dried in vacuo.
Figure imgf000054_0001
Resin bound, side chain protected BNP-32b, carrying an ivDde protecting group at Lysl4, was first boc-protected at the N-terminus, deprotected at Lysl4 position (see Materials and Methods) and then reacted with cώ-cyclohexane-l,2-dicarboxylic anhydride as described above for 29a.
Example 30
Synthesis of BNP-linker-thiols 30a and 30b.
Figure imgf000054_0002
30a
H2N-(CH2)2-N(CH3)-(CH2)5-CONH-(CH2)2-STrt 28 (5.2 mg, 0.01 mmol), PyBOP (5.2 mg, 0.01 mmol) and DIEA (7.0 μl, 0.04 mmol) were dissolved in DMF (300 μl) and added to resin bound, side chain protected BNP 29a (50 mg, 0.005 mmol). Incubation for 2 h at RT, the resin was washed with DMF (1Ox), DCM (1Ox) and dried in vacuo. The product was cleaved from the resin and purified by RP-HPLC. Yield: 9.8 mg MS 30a: m/z 947.6 = [M+4H]4+, 1263.1 = [M+3H]3+ (MW calculated = 3786.3 g/mol)
Figure imgf000054_0003
30b
30b was synthesized as described above except for the use of resin bound BNP derivative 29b instead of 29a. Yield: 7.4 mg MS 30b: m/z 947.5 = [M+4H]4+, 1263.0 = [M+3H]3+ (MW calculated = 3786.3 g/mol)
Example 31
Synthesis of 40KDa-PEG-linker-BNP conjugates 31a and 31b
Figure imgf000055_0001
31a
30a (4 mg) was dissolved in 1:1 H2O/MeCN containing 0.1 % TFA (200 μl). A solution of PEG40KDa-maleimide (42.2 mg) in 1 :1 H2O/MeCN (1 ml) and phosphate buffer (15 μl, pH 7.4, 0.5 M) was added. The solution was incubated at RT, after 5 min AcOH (20 μl) was added and 31a was purified by cation exchange chromatography, desalted and lyophilized. Yield: 2.0 mg
Figure imgf000055_0002
31b 31b was synthesized as described for 31a except for the use of 30b instead of 30a. Yield: 16.8 mg
Example 32
Synthesis of linker 32
Figure imgf000055_0003
32 3-Bromopropionylchloride (62.5 μl, 0.62 mmol) was dissolved in 0.5 ml CH2Cl2 and added to a solution of H2N-CH2-CH2-STiI (200 mg, 0.56 mmol), DIEA (196 μl, 1.1 mmol) in CH2Cl2 (1 ml). The mixture was stirred for 1 h at RT. The reaction mixture was acidified with AcOH (100 μl) and the solvent was removed in vacuo. The residue was purified over silica gel (heptane/EtOAc = 1 : 1) to obtain Br-(CH2)2CONH-(CH2)2-STrt. Yield: 223 mg (0.49 mmol, 87 %) MS Br-(CH2)2CONH-(CH2)2-STrt: 478.7 = [M+Na]+, (MW calculated = 454.7 g/mol)
JV-Alloc-ethylenediamine HCl-salt (43.5 mg, 0.24 mmol) and DIEA (38 μl, 0.22 mmol) were added to a solution of Br-(CH2)2CONH-(CH2)-STrt (100 mg, 0.22 mmol) and Na2CO3 (93 mg, 0.87 mmol) in DMF (1 ml). The reaction mixture was stirred for 10 h at 70 0C. After cooling down to RT the reaction mixture was diluted with 4 ml (MeCNZH2O = 25:75, with 0.1 % TFA) and purified by HPLC to get Alloc-NH-(CH2)2-NH-(CH2)2-CONH-(CH2)2-STrt. Yield: 61 mg (0.096 mmol, 44 %, TFA salt) MS Alloc-NH-(CH2)2-NH-(CH2)2-CONH-(CH2)2-STrt: 540.8 = [M+Na]+, (MW calculated = 517.8. g/mol)
Alloc-NH-(CH2)2-NH-(CH2)2-CONH-(CH2)2-STrt (60.9 mg, 0.096 mmol) was dissolved in CH2Cl2 and BoC2O (42 mg, 0.19 mmol) was added. The solution was stirred for 20 h at RT. After completion the reaction was quenched by addition of 70 μl AcOH and the solvent was removed in vacuo. The residue was diluted with 4 ml MeCNZH2O (25:75, with 0.1 % TFA) and purified by RP-HPLC to give Alloc-NH-(CH2)2-N(Boc)-(CH2)2-CONH-(CH2)2-STrt. Yield: 53.3 mg (0.086 mmol, 89 %) MS Alloc-NH-(CH2)2-N(Boc)-(CH2)2-CONH-(CH2)2-STrt: 640.6 = [M+Na]+, (MW calculated = 617.9. g/mo 1)
Alloc-NH-(CH2)2-N(Boc)-(CH2)2-CONH-(CH2)2-STrt (48.3 mg, 0.078 mmol) was dissolved in THF, triethylammoniumformat (62 μl) and Pd(PPh3)4 (16 mg) were added. The solution was stirred for 12 h at RT and monitored by MS. After completion the solvent was removed in vacuo. The residue was dissolved in MeCNZH2O (50:50, with 0.1 % TFA) and purified by RP-HPLC to give H2N-(CH2)2-N(Boc)-(CH2)2-CONH-(CH2)2-STrt (31). Yield: 20.1 mg (0.031 mmol, 40 %, TFA-salt) MS 31: 534.6 = [M+H]+, 556.6 = [M+Na]+, (MW calculated = 533.5 g/mol) Example 33
Synthesis of BNP-linker-thiols 33a and 33b
Figure imgf000057_0001
33a
33a was synthesized as described for 30a except for the use of 32 instead of 28.
Yield: 8.0 mg
MS 33a: m/z 933.5 = [M+4H]4+, 1244.3 = [M+3H]3+ (MW calculated = 3729.9 g/mol)
Figure imgf000057_0002
33b
33b was synthesized as described for 30b except for the use of 32 instead of 28. Yield: 5.0 mg
MS 33b: m/z 933.5 = [M+4H]4+, 1244.3 = [M+3H]3+ (MW calculated = 3715.9 g/mol)
Example 34
Synthesis of 40KDa-PEG-linker-BNP conjugates 34a and 34b
Figure imgf000057_0003
34a
33a (4.3 mg) was dissolved in 1 :1 H2O/MeCN containing 0.1 % TFA (200 μl). A solution of
PEG40KDa-maleimide (46.8 mg) in 1 :1 H2O/MeCN (1 ml) and phosphate buffer (20 μl, pH 7.4, 0.5 M) was added. The solution was incubated at RT, after 5 min AcOH (20 μl) was added and 34a was purified by cation exchange chromatography, desalted and lyophilized. Yield: 9.7 mg
Figure imgf000058_0001
34b
34b was synthesized as described for 34a except for the use of 33b instead of 33a. Yield: 11.5 mg
Example 35
Synthesis of Linker 35
Figure imgf000058_0002
35 Bromoacetylbromide (54 μl, 0.62 mmol) was dissolved in 0.5 ml CH2Cl2 and added to a solution Of H2N-CH2-CH2-STiI (200 mg, 0.56 mmol) and DIEA (196 μl, 1.1 mmol) in CH2Cl2 (1 ml). The mixture was stirred for 1 h at RT. The reaction mixture was acidified with AcOH (100 μl) and the solvent was removed in vacuo. The residue was purified over silica gel (heptane/EtOAc = 1 :1) to obtain product Br-CH2-CONH-(CH2)2-STrt. Yield: 245 mg (0.55 mmol, 99 %)
MS Br-CH2-CONH-(CH2)2-STrt: 462.4 = [M+Na]+, (MW calculated = 440.4 g/mol)
JV-Alloc-ethylenediamine HCl-salt (45 mg, 0.25 mmol) and DIEA (79 μl, 0.45 mmol) was added to a solution of Br-CH2-CONH-(CH2)2-STrt (100 mg, 0.23 mmol) in DMF (1 ml). The reaction mixture was stirred for 1O h at 70 0C. After cooling down to RT the reaction mixture was diluted with H20/Et20 (1 :1, 40 ml) and the layers were separated. The aqueous layer was extracted several times with Et2O. The combined organic layers were dried with MgSO4, filtered and the solvent was removed in vacuo. The residue was purified over silica gel (DCM/MeOH = 95:5) to give Alloc-NH-(CH2)2-NH-CH2-CONH-(CH2)2-STrt. Yield: 94 mg (0.186 mmol, 82 %, contains residual DMF)
MS Alloc-NH-(CH2)2-NH-CH2-CONH-(CH2)2-STrt: 526.8 = [M+Na]+, (MW calculated = 503.8. g/mol)
Alloc-NH-(CH2)2-NH-CH2-CONH-(CH2)2-STrt (94 mg, 0.186 mmol, with DMF)) was dissolved in CH2CI2 and BOC2O (81 mg, 0.37 mmol) was added. The solution was stirred for
20 h at RT. After completion the reaction was quenched by addition of 100 μl AcOH and the solvent was removed in vacuo. The residue was diluted with 4 ml MeCN/F^O (25:75, with
0.1 % TFA) and purified by RP-HPLC to give Alloc-NH-(CH2)2-N(Boc)-CH2-CONH-(CH2)2-
STrt.
Yield: 34.7 mg (0.057 mmol, 26 %)
MS Alloc-NH-(CH2)2-N(Boc)-CH2-CONH-(CH2)2-STrt: 603.9 = [M+Na]+, (MW calculated = 603.9. g/mol)
Alloc-NH-(CH2)2-N(Boc)-CH2-CONH-(CH2)2-STrt (34.7 mg, 0.048 mmol) was dissolved in THF, triethylammoniumformate (38 μl) and Pd(PPtLs)4 (5 mg) were added. The solution was stirred for 12 h at RT and monitored by MS. After completion the solvent was removed in vacuo. The residue was dissolved in MeCN/H2θ (50:50, with 0.1 % TFA) and purified by RP-HPLC to give H2N-(CH2)2-N(Boc)-CH2-CONH-(CH2)2-STrt 35. Yield: 12.6 mg (0.019 mmol, 42 %, TFA-salt) MS 35: 520.1 = [M + H]+, 542.2 = [M + Na]+, (MW calculated = 519.2 g/mol)
Example 36
Synthesis of BNP-linker-thiols 36a and 36b
Figure imgf000059_0001
36a
36a was synthesized as described for 30a except for the use of 35 instead of 28. Yield: 9.1 mg MS 36a: m/z 930.0 = [M+4H]4+, 1239.6 = [M+3H]3+ (MW calculated = 3715.9 g/mol)
Figure imgf000060_0001
36b
36b was synthesized as described for 30b except for the use of 35 instead of 28. Yield: 8.0 mg
MS 36b: m/z 929.9 = [M+4H]4+, 1239.5 = [M+3H]3+ (MW calculated = 3715.9 g/mol)
Example 37
Synthesis of 40KDa-PEG-linker-BNP conjugates 37a and 37b
Figure imgf000060_0002
37a
36a (4.2 mg) was dissolved in 1 :1 H2O/MeCN containing 0.1 % TFA (200 μl). A solution of PEG40KDa-maleimide (68 mg) in 1:1 H2O/MeCN (1 ml) and phosphate buffer (20 μl, pH 7.4, 0.5 M) was added. The solution was incubated at RT, after 5 min AcOH (20 μl) was added and 37a was purified by ion exchange chromatography, desalted and lyophilized. Yield: 16 mg
Figure imgf000060_0003
37b
37b was synthesized as described for 37a except for the use of 36b instead of 36a. Yield: 18.5 mg
Example 38
Synthesis of linker-exendin conjugates
Linker-exendin conjugates were synthesized according to general synthesis method A, B, C, D, E or F.
Figure imgf000061_0001
Method A
Synthesis: Diacid anhydride (0.2 mmol) and pyridine (0.2 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to side chain protected exendin-4 on resin (2 μmol) and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). PyBOP (0.1 mmol) and diamine (0.1 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to resin and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). Exendin- linker conjugates were cleaved and purified by RP-HPLC as described in "Materials and Methods".
Method B
Synthesis: As described for Method A except that diacid anhydride and pyridine are replaced by diacid (0.2 mmol), HOBt (0.2 mmol), DIC (0.2 mmol), and collidine (0.4 mmol).
Method C
Synthesis. Diamine (0.6 mmol) was dissolved in 1 ml of dry DCM and diacid anhydride (0.4 mmol) was added. Mixture was stirred for 60 min at room temperature. DCM was removed, the residue was dissolved in ACN/water/AcOH, and amino acid was purified by RP-HPLC and lyophilized. Amino acid (0.1 mmol), HOBt (0.1 mmol), DIC (0.1 mmol), and collidine (0.2 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to exendin-4 on resin (2 μmol) and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). Exendin- linker conjugates were cleaved and purified by RP-HPLC as described in "Materials and Methods".
Method D
Synthesis: Diacid anhydride (0.2 mmol) and pyridine (0.2 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to exendin-4 on resin (2 μmol) and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). PyBOP (0.1 mmol), HOBt (0.1 mmol), and collidine (0.4 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to resin and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). Diamine (0.1 mmol) and DIEA (0.3 mmol) were dissolved in a mixture of 0.4 ml of DMF and 0.4 ml of EtOH. Mixture was added to resin and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). Exendin- linker conjugates were cleaved and purified by RP-HPLC as described in "Materials and Methods".
Method E Synthesis: Fmoc amino acid (0.1 mmol), PyBOP (0.1 mmol) and DIEA (0.2 mmol) were dissolved in 0.3 ml of dry DMF. Mixture was added to exendin-4 on resin (2 μmol) and agitated for 30 min at room temperature. Fmoc protecting group was removed by incubating resin in DMF/piperidine 4/1 (v/v) for 2 x 10 min. Resin was washed with DMF (10 times) and DCM (10 times). p-Nitrophenyl chloroformate (0.1 mmol) was dissolved in 0.3 ml of dry THF and DIEA (0.2 mmol). Mixture was added to resin and agitated for 30 min at room temperature. Resin was washed with DCM (10 times). Diamine (0.1 mmol) was dissolved in 0.3 ml of DMF. Mixture was added to resin and agitated for 30 min at room temperature. Resin was washed with DMF (10 times). Exendin- linker conjugates were cleaved and purified by RP-HPLC as described in "Materials and Methods".
Method F
Synthesis: as described for Method A, followed by fmoc-deprotection and acetylation: Fmoc protecting group was removed as by incubating resin in DMF/piperidine 4/1 (v/v) for 2 x 10 min. Resin was washed with DMF (10 times). Acetylation was performed by incubating resin with acetic anhydride/pyridine/DMF 1/1/2 (v/v/v) for 30 min. Resin was washed with DMF
(10 times).
Exendin- linker conjugates were cleaved and purified by RP-HPLC as described in "Materials and Methods".
Further details concerning compound numerals, starting materials, synthesis method, molecular weight (MW) and MS data are given in Fig. 2. Example 39 Synthesis of hydrogel-linker-exendin conjugates 39
hydrogel
Figure imgf000063_0001
Maleimide-functionalized hydrogel microparticles were synthesized as described in EP 1 625 856 A1. 30 mg of maleimide-derivatized hydrogel microparticles (loading 40 μmol/g, 1.2 μmol) were reacted with 6 mg of compound 25a (1.32 μmol, 1.1 eq) in 600μl 20/80 (v/v) acetonitrile/50 mM phosphate buffer (pH 7.4) for 10 min to give exendin- linker loaded hydrogel microparticles 39. The loaded hydrogel 39 was washed 5 times with 50/50 (v/v) acetonitrile/water and three times with water.
Example 40
Synthesis of Linker 40
Figure imgf000064_0001
Fmoc- AIa-OH (250 mg, 0.8 mmol) and DIEA (170 μL, 1,0 mmol) were dissolved in DCM (2 mL), added to 2-chlorotrityl chloride resin (312 mg, 1.3 mmol/g) and agitated for 45 min at RT. Methanol (0.6 mL) was added and the resin was incubated for another 15 min. The resin was washed with DCM (1Ox) and DMF (1Ox). Fmoc-deprotection and urea formation was achieved according to general procedures (see Materials and Methods) by reaction with linker intermediate 5a, the product was cleaved from the resin and purified by RP-HPLC. Yield: 53 mg MS 40: m/z 604,4 [M+H]+ (MW calculated = 603,8 g/mol)
Example 41
Synthesis of exendin-linker conjugate 41
Figure imgf000064_0002
40 (HCl salt, 14.0 mg, 0.02 mmol), PyBOP (10.2 mg, 0.02 mmol) and DIEA (17 μL, 0.1 mmol) were dissolved in DMF (300 μL), immediately added to resin bound, side chain protected exendin (100 mg, 10 μmol) and incubated for 4 h at RT. The resin was washed with DMF (1Ox), DCM (1Ox) and dried in vacuo. The product was cleaved from the resin and purified by RP-HPLC. Yield: 5.4 mg
MS 40: m/z 1510.9 = [M+3H]3+ (MW calculated = 4530.1 g/mol)
Example 42
Synthesis of fatty acid-linker conjugate 42
Figure imgf000065_0001
41 (1.6 mg) was dissolved in 200 μl 3/1 acetonitrile/water and 1 (0.11 mg) in 200 μl of 3/1 acetonitrile/water was added. 30 μl of 0.25 M sodium phosphate buffer was added, the reaction was stirred for 5 min, after which 42 was purified by RP-HPLC. MS 42: m/z 1870.2 = [M+3H]3+ (MW calculated = 5608.4 g/mol).
Example 43
Synthesis of hydrogel-linker-exendin conjugate 43
Figure imgf000065_0002
43 was synthesized as described for 39 except for the use of 41 instead of 25a.
Example 44
Synthesis of Linker 44
Figure imgf000066_0001
44 was synthesized as described for 40 except for the use of 28 instead of 5a. Yield: 74 mg MS 44: m/z 605,4 [M+H]+ (MW calculated = 604,8 g/mol)
Example 45
Synthesis of exendin-linker conjugate 45
Figure imgf000066_0002
45 was synthesized as described for 41 except for the use of 44 instead of 40.
Yield: 6.0 mg
MS 45: m/z 1511.3 = [M+3H]3+ (MW calculated = 4531.1 g/mol)
Example 46
Synthesis of fatty acid-linker conjugate 46
Figure imgf000066_0003
46 46 was synthesized as described for 42 except for the use of 45 instead of 41.
MS 46: m/z 1870.5 = 3
Figure imgf000066_0004
(MW calculated = 5609,5 g/mol).
Example 47 Synthesis of linker intermediate 47
TrtS'
47
TrtS'
Tritylsulfϊde (247 mg, 0.89 mmol) was suspended in 1 ml DMSO. DBU (152 μl, 1.02 mmol) and 6-bromohexan-l-ol (173 mg, 0.96) were added and mixture was stirred for 5 min at RT.
Reaction mixture was dissolved in 20 ml ethylacetate and washed with 1 N H2SO4 (2x) and brine (3x). Organic layer was dried (Na2SO4) and volatiles were removed in vacuo. Product was purified by flash chromatography on silica (heptane/ AcOEt 1/1).
Yield 283 mg (S-trityl)-6-mercaptohexan-l-ol
(S-Trityl)-6-mercaptohexan-l-ol (466 mg, 1.24 mmol) was dissolved in 3.5 ml DCM, 0.5 ml
DMSO and 0.6 ml NEt3, and cooled in an ice bath. Sθ3-pyridine (408 mg, 2.57 mmol) was suspended in 0.5 ml DMSO and added to reaction mixture. Ice bath was removed and reaction was stirred for 60 min at RT. Reaction mixture was dissolved in 20 ml Et2O and extracted with 1 N H2SO4 (2x) and brine (3x). Organic layer was dried (Na2SO4) and volatiles were removed in vacuo. Product was purified by flash chromatography on silica (heptane/ AcOEt
1/1).
Yield: 390 mg (S-trityl)-6-mercaptohexan-l-al 47
MS 47: m/z 243,1 = [Trt]+ , 413.1 = [M+K]+ (MW calculated = 374.4 g/mol)
Example 48
Synthesis of linker 48
Figure imgf000067_0001
Fmoc- AIa-OH (250 mg, 0.8 mmol) and DIEA (170 μL, 1,0 mmol) were dissolved in DCM (2 rnL), added to 2-chlorotrityl chloride resin (312 mg, 1.3 mmol/g) and agitated for 45 min at RT. Methanol (0.6 mL) was added and the resin was incubated for another 15 min. The resin was washed with DCM (1Ox) and DMF (1Ox). Fmoc-deprotection and urea formation was achieved according to general procedures (see Materials and Methods) by reaction with ethylene diamine. For reductive alkylation 47 (299 mg, 0.8 mmol) and Na(OAc)3BH (340 mg, 1.6 mmol) were dissolved in 0,5 mL DMF, 0.5 ml MeOH and 10 μL AcOH, added to resin and agitated for 2 h at RT. Resin was washed with DMF (1Ox) and DCM (1Ox). Boc protection was performed by agitating resin in a solution of boc anhydride (218 mg, 1.0 mmol) and DIEA (170 μL, 1.0 mmol) in DCM. Resin was washed with DCM (1Ox) and product was cleaved from the resin and purified by RP-HPLC. Yield: 34 mg MS 48: m/z 634.2 [M+H]+ (MW calculated = 633.9 g/mol)
Example 49
Synthesis of exendin-linker conjugate 49
Figure imgf000068_0001
49 was synthesized as described for 41 except for the use of 48 instead of 40. Yield: 4.8 mg MS 49: m/z 1487.3 = [M+3H]3+ (MW calculated = 4460.0 g/mol)
Example 50
Synthesis of hydrogel-linker-exendin conjugate 50
Figure imgf000068_0002
50 was synthesized as described for 39 except for the use of 49 instead of 25a. Example 51
Release kinetics in vitro
Release of drug molecule from 38a to 38z, 38aa to 38ab, 4, 5, 9a, 9b, 9c, 10, 13a,15, 19a, 19b, 22, 26a to 26c, 31a, 31b, 34a, 34b, 37a, 37b, 42, 43, 46, and 50 was effected by hydrolysis in buffer at pH 7.4 and 37°C or pH 4 and 37°C as described in "Materials and Methods".
Compound ti/2 buffer A (pH ti/2 buffer B (pH
7.4) 4.0)
38a < Ih 13 h
38b 2O h 72 d
38c >3 m > 3m
38d 58 d n.d.
38e 41 d n. d.
38f 23 h 114 d
38g 19 d none
38h 47 d none
38i 69 h 108 d
38j 16 d n.d.
38k 40 mm 6 d
381 16 h n.d.
38m 17 h 66 d
38n 18 d n.d.
38o 11-12 h 22 d
38p 26 d 178 d
38q 26 d 21O d
38r 26 h 47 d
38s 80 mm 8Oh
38t 96 mm 67 h
38u 51 d none
38v 47 d none
38w 8 d 3,2 a
38x 72 d n.d.
38y 11-14 h 105 d
38z H d 1,6 a
38aa 4O h 65 d
38ab 2O h 2O d
38ac 14h n.d.
38ad 18h n.d.
4 15 d n.d.
5 22 h n.d.
9a 340 h n.d
9b 360 h n.d
9c 12O h n.d
10 130 h n.d 13a 120 h n.d
13b 16O h n.d
15 16O h n.d
19a 31h n.d
19b 18h n.d
22 4Od n.d
26a 34d n.d
26b 4Od n.d
26c 18d n.d
31a 22h n.d
31b 95h n.d
34a 42h n.d
34b 205h n.d
37a 138h n.d
37b 639h n.d
42 1Od n.d
43 17d n.d
46 13d n.d
50 35d n.d
Example 52
Release kinetics in vivo - in vitro/in vivo correlation Release kinetics in vivo were determined by comparing the pharmacokinetics of 13a with the pharmacokinetics of 13c and 13b with 13d, respectively, after intravenous injection into rat. Animal studies were performed at Heidelberg Pharma AG, Heidelberg, Germany. 13a (27 mg) was dissolved in 3.5 ml PBS and 500 μl of the resulting solution were injected intravenously into six rats each. Male SD rats with approximately 270 g weight were used. Blood samples were drawn at t = 0, 2 h, 24 h, 32 h, 48 h, 72 h, 96 h, 120 h, and 168 h, plasma was prepared, and plasma was analyzed for fluorescein fluorescence using a Perkin-Elmer LS 5OB spektrometer.
Pharmacokinetics of 13c were determined as described for 13a. Pharmacokinetics of 13b and 13d were determined as described for 13a, except for the use of 20 mg 13 b and 13d each in 2.5 ml PBS and four rats.
Linker hydrolysis half-life was calculated from the ratio of fluorescence of 13a compared to fluorescence of 13c and 13b compared to 13d, respectively, at the respective time points. Half-life of in vivo linker hydrolysis was determined to be 115 h and 160 h for 13a and 13b, respectively, which is in excellent correlation to the half-life of in vitro linker hydrolysis of 12O h and 16O h for 13a and 13b, respectively.
Fig. 3 shows in vivo and in vitro linker cleavage data of 13b, wherein in vivo (triangles) and in vitro (diamonds) cleavage kinetics are shown by semilogarithmic representation.
Abbreviations:
Acp 4-(2-aminoethyl)- 1 -carboxymethyl-piperazine
AcOH acetic acid
Boc t-butylo xy carbony 1
Dab 2,4-diaminobutyric acid
DBU l,3-diazabicyclo[5.4.0]undecene
DCM dichloromethane
Dda dodecanoic acid
DIC diisopropylcarbodiimide
DIEA diisopropylethylamine
DMAP dimethy lamino -pyridine
DMF N,N-dimethylformamide
DMSO dimethy lsulfo xide
EDTA ethylenediaminetetraacetic acid eq stoichiometric equivalent
Fmoc 9-fluorenylmethoxycarbonyl
HATU O-(7-Azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HFIP hexafluoroisopropanol
HEPES N-(2-hydroxyethyl) piperazine-N'-(2-ethanesulfonic acid)
HOBt N-hydroxybenzotriazole ivDde l-(4,4-Dimethyl-2,6-dioxo-cyclohexylidene)-3-methylbutyl
LCMS mass spectrometry-coupled liquid chromatography
MaI 3-maleimido propionyl
Mmt 4-methoxytrityl
MS mass spectrum
MW molecular mass n.d. not determined
PfpOH pentafluorophenol
PyBOP benzotriazole- 1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
RP-HPLC reversed-phase high performance liquid chromatography RT room temperature
SEC size exclusion chromatography
Sue succinimidopropionyl
TCP 2-chlorotrityl chloride resin
TES triethylsilane
TMOB 2,4,6-trimethoxybenzyl
TFA trifluoroacetic acid
THF tetrahydrofurane
UV ultraviolet
VIS visual

Claims

Patent Claims
1. A prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein
-D is a nitrogen containing biologically active moiety; and
-L is a non-bio logically active linker moiety -L1 represented by formula (I),
Figure imgf000074_0001
wherein the dashed line indicates the attachment to the nitrogen of the biologically active moiety by forming an amide bond;
X is C(R4R4a); N(R4); O; C(R4R4a)-C(R5R5a); C(R5R5a)-C(R4R4a); C(R4R4a)- N(R6); N(R6)-C(R4R4a); C(R4R4a)-O; or O-C(R4R4a);
XI is C; or S(O);
X2 is C(R7, R7a); or C(R7, R7a)-C(R8, R8a);
X3 is O; S; or N-CN;
R1, Rla, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6, R7, R7a, R8, R8a are independently selected from the group consisting of H; and Ci_4 alkyl;
Optionally, one or more of the pairs Rla/R4a, Rla/R5a, R4a/R5a, R7a/R8a form a chemical bond; Optionally, one or more of the pairs RVRla, R2/R2a, R4/R4a, R5/R5a, R7/R7a, R8/R8a are joined together with the atom to which they are attached to form a C3_7 cycloalkyl; or 4 to 7 membered heterocyclyl;
Optionally, one or more of the pairs RVR4, RVR5, RVR6, R4/R5, R4/R6, R7/R8,
R2/R3 are joined together with the atoms to which they are attached to form a ring A;
Optionally, R3/R3a are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle;
A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3_io cycloalkyl; 4 to 7 membered heterocyclyl; and 9 to 11 membered heterobicyclyl; and
wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein
L2 is a single chemical bond or a spacer; and
Z is a carrier group.
2. The prodrug of claim 1 , wherein X3 is O.
3. The prodrug of claim 1 or 2, wherein X is N(R4), X1 is C and X3 is O.
4. The prodrug of any of claims 1 to 3, wherein X2 is C(R7R7a).
5. The prodrug of any of claims 1 to 4, wherein L1 is selected from the group consisting of
Figure imgf000076_0001
Figure imgf000076_0002
Figure imgf000077_0001
wherein R is H; or C1-4 alkyl; Y is NH; O; or S; and
Figure imgf000077_0002
, , , , , ,
X 1 , X2 have the meaning as indicated in claim 1.
6. The prodrug of any of claims 1 to 5, wherein L is selected from the group consisting of
Figure imgf000078_0001
Figure imgf000078_0002
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
wherein R has the meaning as indicated in claim 5.
The prodrug of any of claims 1 to 6, wherein L2 is a single chemical bond; or L2-Z is COOR9; OR9; C(O)R9; C(O)N(R9R9a); S(O)2N(R9R9a); S(O)N(R9R9a); S(O)2R9; S(O)R9; N(R9)S(O)2N(R9aR9b); SR9; N(R9R9a); OC(O)R9; N(R9)C(O)R9a;
N(R9)S(O)2R9a; N(R9)S(O)R9a; N(R9)C(O)OR9a; N(R9)C(O)N(R9aR9b); OC(O)N(R9R9a); T; Ci-50 alkyl; C2-50 alkenyl; or C2-50 alkynyl, wherein T; Ci-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R10, which are the same or different and wherein Ci-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T- 11 11 11
Figure imgf000082_0001
R , R , 9aa, r R, 9b are independently selected from the group consisting of H; Z; T; and Ci-50 alkyl; C2-50 alkenyl; or C2-50 alkynyl, wherein T; Ci-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R10, which are the same or different and wherein Ci-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of T, -C(O)O-; -
Figure imgf000082_0002
T is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3_i0 cycloalkyl; 4 to 7 membered heterocyclyl; or 9 to 11 membered heterobicyclyl, wherein t is optionally substituted with one or more R10, which are the same or different;
Figure imgf000082_0003
Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
R11, Rl la, R12, R12a, R12b are independently selected from the group consisting of H; Z; or alkyl, wherein alkyl is optionally substituted with one or more halogen,
Figure imgf000082_0004
which are the same or different;
provided that one of R9, R9a, R9b, R10, R11, Rl la, R12, R12a, R12b is Z.
8. The prodrug of any of claims 1 to 7, wherein L2 is a Ci_2o alkyl chain, which is optionally interrupted by one or more groups independently selected from -O-; and C(O)N(R3aa); optionally substituted with one or more groups independently selected from OH; and C(O)N(R3aaR3aaa); and wherein R3aa, R3aaa are independently selected from the group consisting of H; and Ci_4 alkyl.
9. The prodrug of any of cairns 1 to 8, wherein L2 has a molecular weight in the range of from 14 g/mol to 750 g/mol.
10. The prodrug of any of claims 1 to 9, wherein L2 is attached to Z via a terminal group
O O
selected from Y ° ; and Y °
11. The prodrug of any of claims 1 to 10, wherein L is represented by formula (Ia)
Figure imgf000083_0001
wherein R4, L2, and Z have the meaning as indicated in claim 1, and wherein R3aa, R3aaa are independently selected from the group consisting of H; and Ci_4 alkyl; or are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle.
12. The prodrug of any of claims 1 to 10, wherein L is represented by formula (Ib)
Figure imgf000083_0002
wherein R1, Rla, R4, L2 and Z have the meaning as indicated in claim 1, and wherein R3aa is H; or Ci-4 alkyl.
13. The prodrug of any of claims 1 to 10, wherein R1 in formula (I) is L2-Z.
14. The prodrug of any of claims 1 to 10, wherein R3 in formula (I) is L2-Z.
15. The prodrug of any of claims 1 to 10, wherein R3, R3a in formula (I) are joined together with the nitrogen atom to which they are attached to form a 4 to 7 membered heterocycle and wherein the heterocycle is substituted with L2-Z.
16. The prodrug of any of claims 1 to 15, wherein D-H is a small molecule bioactive agent or a biopolymer.
17. The prodrug of any of claims 1 to 16, wherein D-H is a biopolymer selected from the group of biopolymers consisting of proteins, polypeptides, oligonucleotides, and peptide nucleic acids.
18. The prodrug of any of claims 1 to 17, wherein D-H is a polypeptide selected from the group of polypeptides consisting of ACTH, adenosine deaminase, agalsidase, alfa-1 antitrypsin (AAT), alfa-1 proteinase inhibitor (API), alteplase, amylins (amylin, symlin), anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal, and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, atosiban, biphalin, bivalirudin, bone-morphogenic proteins, bovine pancreatic trypsin inhibitor (BPTI), cadherin fragments, calcitonin (salmon), collagenase, complement
Cl esterase inhibitor, conotoxins, cytokine receptor fragments, DNase, dynorphine A, endorphins, enfuvirtide, enkephalins, erythropoietins, exendins, factor VII, factor Vila, factor VIII, factor Villa, factor IX, fibrinolysin, fibroblast growth factor (FGF), growth hormone releasing peptide 2 (GHRP2), fusion proteins, follicle-stimulating hormones, gramicidin, ghrelin, desacyl-ghrelin, granulocyte colony stimulating factor
(G-CSF), galactosidase, glucagon, glucagon-like peptides, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GM-CSF), human heat shock proteins (HSP), phospholipase-activating protein (PLAP), gonadotropin chorionic (hCG), hemoglobins, hepatitis B vaccines, hirudin, human serine protease inhibitor, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukins (1 alfa, 1 beta, 2, 3, 4, 6, 10, 11, 12, 13, 21), IL-I receptor antagonist (rhlL-lra), insulins, insulin like growth factors, insulin-like growth factor binding protein (rhIGFBP), interferons (alfa 2a, alfa 2b, alfa 2c, beta Ia, beta Ib, gamma Ia, gamma Ib), intracellular adhesion molecule, keratinocyte growth factor (KGF), P-selectin glycoprotein ligand (PSGL), transforming growth factors, lactase, leptin, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptides (ANP, BNP, CNP and fragments), neuropeptide Y, pancrelipase, pancreatic polypeptide, papain, parathyroid hormone, PDGF, pepsin, peptide YY, platelet activating factor acetylhydrolase (PAF-AH), prolactin, protein C, thymalfasin, octreotide, secretin, sermorelin, soluble tumor necorsis factor receptor (TNFR), superoxide dismutase (SOD), somatropins (growth hormone), somatoprim, somatostatin, streptokinase, sucrase, terlipressin, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrotropin, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), TSH, urodilatin, urate oxidase, urokinase, vaccines, vascular endothelial growth factor (VEGF), vasoactive intestinal peptide, vasopressin, ziconotide, lectin and ricin.
19. The prodrug of any of claims 1 to 18, wherein D-H is a protein prepared by recombinant DNA technologies.
20. The prodrug of any of claims 1 to 19, wherein D-H is a protein selected from the group of proteins consisting of antibody fragments, single chain antigen binding proteins, catalytic antibodies and fusion proteins.
21. The prodrug of any of claims 1 to 16, wherein D-H is a small molecule bio active agent selected from the group of agents consisting of central nervous system-active agents, anti-infective, anti-allergic, immunomodulating, anti-obesity, anticoagulants, antidiabetic, anti-neoplastic, antibacterial, anti-fungal, analgesic, contraceptive, anti- inflammatory, steroidal, vasodilating, vasoconstricting, and cardiovascular agents with at least one primary or secondary amino group.
22. The prodrug of any of claims 1 to 16 and 21, wherein D-H is a small molecule bioactive agent selected from the group of agents consisting of acarbose, alaproclate, alendronate, amantadine, amikacin, amineptine, aminoglutethimide, amisulpride, amlodipine, amotosalen, amoxapine, amoxicillin, amphetamine, amphotericin B, ampicillin, amprenavir, amrinone, anileridine, apraclonidine, apramycin, articaine, atenolol, atomoxetine, avizafone, baclofen, benazepril, benserazide, benzocaine, betaxolol, bleomycin, bromfenac, bro faro mine, carvedilol, cathine, cathinone, carbutamid, cefalexine, clinafloxacin, ciprofloxacin, deferoxamine, delavirdine, desipramine, daunorubicin, dexmethylphenidate, dexmethylphenidate, diaphenylsulfon, dizocilpine, dopamin, dobutamin, dorzolamide, doxorubicin, duloxetine, eflornithine, enalapril, epinephrine, epirubicin, ergoline, ertapenem, esmolol, enoxacin, ethambutol, fenfluramine, fenoldopam, fenoterol, fmgolimod, flecainide, fluvoxamine, fosamprenavir, frovatriptan, furosemide, fluoexetine, gabapentin, gatifloxacin, gemiflocacin, gentamicin, grepafloxacin, hexylcaine, hydralazine, hydrochlorothiazide, icofungipen, idarubicin, imiquimod, inversine, isoproterenol, isradipine, kanamycin A, ketamin, labetalol, lamivudine, levobunolol, levodopa, levothyroxine, lisinopril, lomefloxacin, loracarbef, maprotiline, mefloquine, melphalan, memantine, meropenem, mesalazine, mescaline, methyldopa, methylenedioxymethamphetamine, metoprolol, milnacipran, mitoxantron, moxifloxacin, norepinephrine, norfloxacin, nortriptyline, neomycin B, nystatin, oseltamivir, pamidronic acid, paroxetine, pazufloxacin, pemetrexed, perindopril, phenmetrazine, phenelzine, pregabalin, procaine, pseudoephedrine, protriptyline, reboxetine, ritodrine, sabarubicin, salbutamol, serotonin, sertraline, sitagliptin, sotalol, spectinomycin, sulfadiazin, sulfamerazin, sertraline, sprectinomycin, sulfalen, sulfamethoxazol, tacrine, tamsulosin, terbutaline, timolol, tirofϊban, tobramycin, tocainide, tosufloxacin, trandolapril, tranexamic acid, tranylcypromine, trimerexate, trovafloxacin, valaciclovir, valganciclovir, vancomycin, viomycin, viloxazine, and zalcitabine.
23. The prodrug of any of claims 1 to 22, wherein Z is a polymer of at least 500 Da or a C8-IS alkyl group.
24. The prodrug of any of claims 1 to 23, wherein Z is selected from the group of optionally crosslinked polymers consisting of poly(propylene glycol), poly(ethylene glycol), dextran, chitosan, hyaluronic acid, alginate, xylan, mannan, carrageenan, agarose, cellulose, starch, hydroxyalkyl starch (HAS), poly(vinyl alcohols), poly(oxazolines), poly(anhydrides), poly(ortho esters), polycarbonates), poly(urethanes), poly(acrylic acids), poly(acrylamides), poly(acrylates), poly(methacrylates), poly(organophosphazenes), polyoxazoline, poly(siloxanes), poly(amides), poly(vinylpyrrolidone), poly(cyanoacrylates), poly(esters), poly(iminocarbonates), poly(amino acids), collagen, gelatin, hydrogel, or a blood plasma protein, and copolymers thereof.
25. The prodrug of any of claims 1 to 24, wherein Z is a protein.
26. The prodrug of any of claims 1 to 25, wherein Z is a protein selected from the group consisting of albumin, transferrin, immunoglobulin.
27. The prodrug of any of claims 1 to 23, wherein Z is a linear or branched poly(ethylene glycol) with a molecular weight from 2,000 Da to 150,000 Da.
28. The prodrug of any of claims 1 to 27, wherein D-H is a GLP-I receptor agonist; L is L1 represented by formula (I) as indicated in claim 1; and Z is a hydrogel.
29. The prodrug of claim 28, wherein the GLP-I receptor agonist is Exendin-4.
30. The prodrug of claim 28 or 29, wherein in formula (I) X is N(R4), X1 is C and X3 is O.
31. The prodrug of any of claims 28 to 30, wherein L is represented by formula (Ia) as indicated in claim 11 or L is represented by formula (Ib) as indicated in claim 12.
32. A prodrug precursor of formula Act-L, wherein L has the meaning as indicated in claim 1 and Act is a leaving group.
33. The prodrug precursor of claim 32, wherein Act is chloride, bromide, fluoride, nitrophenoxy, imidazolyl, N-hydroxysuccinimidyl, N-hydroxybenzotriazolyl, N- hydroxyazobenzotriazolyl, pentafluorophenoxy, 2-thiooxo-thiazolidinyl, or N- hydroxysulfosuccinimidyl.
34. A pharmaceutical composition comprising a prodrug of any of claims 1 to 31 or a pharmaceutical salt thereof together with a pharmaceutically acceptable excipient.
35. A prodrug of any of claims 1 to 31 or a pharmaceutical composition of claim 30 for use as a medicament.
36. A method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more conditions comprising administering to said patient a therapeutically effective amount of a prodrug of any of claims 1 to 31 or a pharmaceutical composition of claim 34 or a pharmaceutically acceptable salt thereof.
PCT/EP2009/051079 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker WO2009095479A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
JP2010544717A JP5588354B2 (en) 2008-02-01 2009-01-30 Prodrugs containing self-cleavable linkers
MX2010008024A MX2010008024A (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker.
DK09706788.8T DK2237799T3 (en) 2008-02-01 2009-01-30 PRODRUG INCLUDING A SELF-SPLITABLE LINKS
LTEP09706788.8T LT2237799T (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker
PL09706788T PL2237799T3 (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker
AU2009209565A AU2009209565B2 (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker
EP21202920.1A EP3981761A3 (en) 2008-02-01 2009-01-30 Intermediates for prodrugs
SI200931976T SI2237799T1 (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker
BRPI0906643A BRPI0906643A2 (en) 2008-02-01 2009-01-30 a prodrug comprising a drug-binder conjugate
US12/865,693 US8906847B2 (en) 2008-02-01 2009-01-30 Prodrug comprising a drug linker conjugate
EP13156350.4A EP2596805B1 (en) 2008-02-01 2009-01-30 Prodrug comprising a drug-linker conjugate
CA2712224A CA2712224C (en) 2008-02-01 2009-01-30 Prodrug comprising a drug linker conjugate
EP09706788.8A EP2237799B1 (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker
RS20190789A RS58948B1 (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker
ES09706788T ES2733355T3 (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker
CN2009801110881A CN101980725B (en) 2008-02-01 2009-01-30 Prodrug comprising a drug linker conjugate
IL207150A IL207150A (en) 2008-02-01 2010-07-22 Prodrug comprising a drug linker conjugate
ZA2010/05413A ZA201005413B (en) 2008-02-01 2010-07-29 Prodrug comprising a self-cleavable linker
HK11106352.6A HK1152240A1 (en) 2008-02-01 2011-06-21 Prodrug comprising a self-cleavable linker
US14/528,362 US20150057221A1 (en) 2008-02-01 2014-10-30 Prodrug comprising a drug linker conjugate
US15/385,179 US20170100490A1 (en) 2008-02-01 2016-12-20 Prodrug Comprising a Drug Linker Conjugate
HRP20191052 HRP20191052T1 (en) 2008-02-01 2019-06-12 Prodrug comprising a self-cleavable linker
CY20191100707T CY1121961T1 (en) 2008-02-01 2019-07-03 PRODRUG CONTAINING A SELF-DISPERSIBLE LINKER
US16/654,667 US20200046725A1 (en) 2008-02-01 2019-10-16 Prodrug Comprising a Drug Linker Conjugate
US17/847,750 US20220331334A1 (en) 2008-02-01 2022-06-23 Prodrug Comprising a Drug-Linker Conjugate
US18/479,445 US20240041897A1 (en) 2008-02-01 2023-10-02 Prodrug comprising a drug linker conjugate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08150973.9 2008-02-01
EP08150973 2008-02-01
EP08170872 2008-12-05
EP08170872.9 2008-12-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/865,693 A-371-Of-International US8906847B2 (en) 2008-02-01 2009-01-30 Prodrug comprising a drug linker conjugate
US14/528,362 Continuation US20150057221A1 (en) 2008-02-01 2014-10-30 Prodrug comprising a drug linker conjugate

Publications (2)

Publication Number Publication Date
WO2009095479A2 true WO2009095479A2 (en) 2009-08-06
WO2009095479A3 WO2009095479A3 (en) 2009-10-01

Family

ID=40823379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/051079 WO2009095479A2 (en) 2008-02-01 2009-01-30 Prodrug comprising a self-cleavable linker

Country Status (23)

Country Link
US (6) US8906847B2 (en)
EP (3) EP2596805B1 (en)
JP (2) JP5588354B2 (en)
CN (1) CN101980725B (en)
AU (1) AU2009209565B2 (en)
BR (1) BRPI0906643A2 (en)
CA (1) CA2712224C (en)
CY (1) CY1121961T1 (en)
DK (2) DK2237799T3 (en)
ES (2) ES2904673T3 (en)
HK (1) HK1152240A1 (en)
HR (1) HRP20191052T1 (en)
HU (1) HUE044174T2 (en)
IL (1) IL207150A (en)
LT (1) LT2237799T (en)
MX (1) MX2010008024A (en)
PL (1) PL2237799T3 (en)
PT (1) PT2237799T (en)
RS (1) RS58948B1 (en)
RU (2) RU2010136023A (en)
SI (1) SI2237799T1 (en)
WO (1) WO2009095479A2 (en)
ZA (1) ZA201005413B (en)

Cited By (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042596A2 (en) * 2008-10-08 2010-04-15 The Uab Research Foundation Photo-activated protecting groups
WO2011012722A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011089216A1 (en) * 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US20120035320A1 (en) * 2010-04-03 2012-02-09 University Of Iowa Research Foundation Polyacridine nucleic acid delivery peptide complexes
WO2012035139A1 (en) 2010-09-17 2012-03-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an exendin linker conjugate
WO2011073234A3 (en) * 2009-12-15 2012-04-19 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
US20120184489A1 (en) * 2009-07-31 2012-07-19 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
WO2013024048A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
WO2013024053A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013024049A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Protein carrier-linked prodrugs
WO2013053856A1 (en) 2011-10-12 2013-04-18 Ascendis Pharma A/S Prevention and treatment of ocular conditions
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN103179979A (en) * 2010-06-24 2013-06-26 印第安纳大学研究及科技有限公司 Amide based glucagon superfamily peptide prodrugs
US8481485B2 (en) 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US8546327B2 (en) 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2013160340A1 (en) 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
WO2013167750A2 (en) 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
US8669228B2 (en) 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
US8697838B2 (en) 2008-01-30 2014-04-15 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
WO2014056923A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma Ophthalmology Division A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
WO2014056915A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2014080730A1 (en) 2012-11-22 2014-05-30 株式会社糖鎖工学研究所 Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof
WO2014084110A1 (en) 2012-11-30 2014-06-05 株式会社糖鎖工学研究所 Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
WO2014173759A1 (en) 2013-04-22 2014-10-30 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2015052154A1 (en) * 2013-10-08 2015-04-16 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-linked il-1ra prodrug
WO2015067791A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
EP2768856A4 (en) * 2011-10-18 2015-05-27 Prolynx Llc Peg conjugates of exenatide
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US9062124B2 (en) 2008-06-17 2015-06-23 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9265723B2 (en) 2009-07-31 2016-02-23 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
US9272048B2 (en) 2008-04-29 2016-03-01 Ascendis Pharma Growth Disorders Division A/S PEGylated recombinant human growth hormone compounds
WO2016110577A1 (en) * 2015-01-09 2016-07-14 Ascendis Pharma A/S Cnp prodrugs
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2016193371A1 (en) 2015-06-05 2016-12-08 Sanofi Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate
WO2016196124A2 (en) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Prodrugs comprising a pyroglutamate linker
US9533056B2 (en) 2010-01-22 2017-01-03 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
US9593156B2 (en) 2012-09-26 2017-03-14 Indiana University Research And Technology Corporation Insulin analog dimers
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
WO2017118704A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
WO2017118693A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
WO2017118698A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
WO2017118703A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
WO2017148883A1 (en) 2016-03-01 2017-09-08 Ascendis Pharma Bone Diseases A/S Pth prodrugs
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9790263B2 (en) 2009-06-16 2017-10-17 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
WO2017186250A1 (en) 2016-04-29 2017-11-02 Defensin Therapeutics Aps Treatment of liver, biliary tract and pancreatic disorders
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2018060310A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
WO2018060312A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
WO2018060311A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
WO2018060314A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
WO2018100174A1 (en) 2016-12-02 2018-06-07 Sanofi Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
WO2018108971A2 (en) 2016-12-13 2018-06-21 Defensin Therapeutics Aps Methods for treating inflammatory conditions of the lungs
US10040850B2 (en) 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
WO2018175788A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
WO2019076675A1 (en) * 2017-10-06 2019-04-25 Instituto De Medicina Molecular Treatment of obesity-related conditions
WO2019092201A2 (en) 2017-11-10 2019-05-16 Defensin Therapeutics Aps Maturation of mucosal defense and gut/lung function in the preterm infant
WO2019101773A2 (en) 2017-11-24 2019-05-31 Defensin Therapeutics Aps Prevention and treatment of graft-versus-host-disease with defensins
US10385107B2 (en) 2014-09-24 2019-08-20 Indiana Univeresity Researc and Technology Corporation Lipidated amide-based insulin prodrugs
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
WO2019219896A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
WO2019229225A1 (en) 2018-05-30 2019-12-05 Sanofi Conjugates comprising an glp-1/glucagon/gip triple receptor agonist, a linker and hyaluronic acid
WO2020064846A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
WO2020064844A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
US10696726B2 (en) 2013-03-14 2020-06-30 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2020141221A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Conjugates of pattern recognition receptor agonists
WO2020141222A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Sustained local drug levels for innate immune agonists
WO2020141225A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Minimization of systemic inflammation
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
WO2020165087A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
WO2020165081A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
US10751417B2 (en) 2017-04-20 2020-08-25 Novartis Ag Sustained release delivery systems comprising traceless linkers
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US10800738B2 (en) 2017-12-05 2020-10-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
USRE48267E1 (en) 2009-05-20 2020-10-20 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254611A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254606A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254609A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254603A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
US10874639B2 (en) 2017-12-05 2020-12-29 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2021136808A1 (en) 2020-01-03 2021-07-08 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
WO2021144249A1 (en) 2020-01-13 2021-07-22 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
US11179467B2 (en) 2015-09-25 2021-11-23 Brightgene Bio-Medical Technology Co., Ltd. Exenatide modifier and use thereof
WO2021245130A1 (en) 2020-06-03 2021-12-09 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
US11224661B2 (en) 2016-01-08 2022-01-18 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
WO2022029178A1 (en) 2020-08-05 2022-02-10 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
WO2022043493A1 (en) 2020-08-28 2022-03-03 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
WO2022053696A1 (en) * 2020-09-11 2022-03-17 Compass Pathfinder Limited Novel safrylamine derivatives having prodrug properties
WO2022064035A1 (en) 2020-09-28 2022-03-31 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
US11357828B2 (en) 2018-09-12 2022-06-14 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
US11389541B2 (en) 2018-10-03 2022-07-19 Novartis Ag Sustained delivery of angiopoetin-like 3 polypeptides
WO2022207798A1 (en) 2021-04-01 2022-10-06 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
US11559482B2 (en) 2009-07-31 2023-01-24 Ascendis Pharma A/S Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2023110727A2 (en) 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
US11786599B2 (en) 2017-03-10 2023-10-17 Quiapeg Pharmaceuticals Ab Releasable conjugates
RU2806753C2 (en) * 2018-05-18 2023-11-07 Асцендис Фарма Боун Дизизис А/С Method of treating or control of hypoparathyroidus using parathrooid hormone (pth) conjugate
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
US11845736B2 (en) 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
US11993577B2 (en) 2021-09-01 2024-05-28 Empathbio, Inc. Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment
WO2024146920A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma Ophthalmology Division A/S Drug conjugates for the treatment of ocular disorders
WO2024146902A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma A/S Methods of producing hydrogel microspheres
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
WO2024184351A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
US12133883B2 (en) 2014-11-18 2024-11-05 Ascendis Pharma Endocrinology Division A/S Polymeric hGH prodrugs

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2237799T3 (en) * 2008-02-01 2019-09-30 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
US9192681B2 (en) 2009-02-24 2015-11-24 Nektar Therapeutics Oligomer-amino acid conjugates
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
US8986609B2 (en) 2009-10-29 2015-03-24 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
CA2840215A1 (en) 2011-06-22 2012-12-27 Abhijit S. BAPAT Conjugate-based antifungal and antibacterial prodrugs
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
AU2013308578A1 (en) * 2012-08-30 2015-04-02 The Scripps Research Institute Small molecules targeting repeat r(CGG) sequences
WO2014187313A1 (en) * 2013-05-21 2014-11-27 成都先导药物开发有限公司 Method for cell membrane permeation for compound
JP6215455B2 (en) * 2013-05-21 2017-10-18 成都先導薬物開発有限公司 Compound administration precursor and drug carrier formulation
KR101768446B1 (en) 2014-03-21 2017-08-17 애니젠 주식회사 Novel Exenatide Analogs and Uses thereof
CN104945499B (en) * 2014-03-31 2019-12-10 博瑞生物医药（苏州）股份有限公司 GLP-1 analogue with modified structure and preparation method thereof
JP5924795B2 (en) 2014-06-13 2016-05-25 テンボロン オイ Complex
EP3215116B1 (en) 2014-11-05 2020-09-30 University of the Sciences in Philadelphia A high molecular weight biodegradable gelatin-doxorubicin conjugate
CN107043406B (en) 2015-11-03 2021-08-17 财团法人工业技术研究院 Compound, linker-drug, and ligand-drug conjugate
WO2017127528A1 (en) * 2016-01-19 2017-07-27 University Of Florida Research Foundation, Inc. Peptoid agonists of fibroblast growth receptors
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
AU2017388894A1 (en) * 2016-12-29 2019-08-08 Development Center For Biotechnology KLK6-mediated CNS-specific antibody prodrug activation
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN109160883B (en) * 2017-11-30 2021-10-08 银隆新能源股份有限公司 Anthraquinone salt positive electrode material and synthetic method thereof
KR102527941B1 (en) 2017-12-06 2023-05-02 어비디티 바이오사이언시스 인크. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
JP7332620B2 (en) 2018-04-10 2023-08-23 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Synthesis of lixisenatide with capping
AU2019250359A1 (en) 2018-04-10 2020-11-26 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
CN109125707B (en) * 2018-10-19 2022-01-04 艾伟伦 GnRH analogue sustained-release composition and preparation method thereof
CN113993522A (en) 2019-04-17 2022-01-28 指南针探路者有限公司 Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin
US11525137B2 (en) 2020-03-19 2022-12-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
CN113842379B (en) * 2021-09-12 2024-04-23 东北农业大学 New application of betaxolol as NDM-1 inhibitor or antibiotic protectant
US11912779B2 (en) 2021-09-16 2024-02-27 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6253997A (en) * 1985-09-03 1987-03-09 Kowa Co Novel amino glycoside and pharmaceutical preparation containing same
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2286232A1 (en) * 1997-04-06 1998-11-05 California Institute Of Technology Dna-binding pyrrole and imidazole polyamide derivatives
EP1623994A3 (en) 1999-05-17 2008-07-16 ConjuChem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP1764360A4 (en) * 2004-07-02 2010-08-11 Sankyo Co Urea derivative
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel polymeric conjugates of a prodrug
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
WO2006073396A1 (en) * 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Analgesic conjugates
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US20090017004A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
PL2237799T3 (en) * 2008-02-01 2019-09-30 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
EP2438930A1 (en) * 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US9018164B2 (en) 2005-11-07 2015-04-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8669228B2 (en) 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
US9089539B2 (en) 2008-01-30 2015-07-28 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
US8697838B2 (en) 2008-01-30 2014-04-15 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
US10098930B2 (en) 2008-04-29 2018-10-16 Ascendis Pharma Endocrinology Division A/S PEGylated Recombinant Human Growth Hormone Compounds
US9272048B2 (en) 2008-04-29 2016-03-01 Ascendis Pharma Growth Disorders Division A/S PEGylated recombinant human growth hormone compounds
US10960053B2 (en) 2008-04-29 2021-03-30 Ascendis Pharma Endocrinology Division A/S PEGylated recombinant human growth hormone compounds
US9062124B2 (en) 2008-06-17 2015-06-23 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
US8546327B2 (en) 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
WO2010042596A3 (en) * 2008-10-08 2010-07-01 The Uab Research Foundation Photo-activated protecting groups
WO2010042596A2 (en) * 2008-10-08 2010-04-15 The Uab Research Foundation Photo-activated protecting groups
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
US8481485B2 (en) 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
USRE48267E1 (en) 2009-05-20 2020-10-20 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
US9790263B2 (en) 2009-06-16 2017-10-17 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9265723B2 (en) 2009-07-31 2016-02-23 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
US20120184489A1 (en) * 2009-07-31 2012-07-19 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
US9457066B2 (en) 2009-07-31 2016-10-04 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
JP2013500951A (en) * 2009-07-31 2013-01-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Prodrugs containing insulin linker conjugates
US9138462B2 (en) 2009-07-31 2015-09-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
WO2011012722A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
US11559482B2 (en) 2009-07-31 2023-01-24 Ascendis Pharma A/S Biodegradable polyethylene glycol based water-insoluble hydrogels
US10682395B2 (en) 2009-12-15 2020-06-16 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
US9919033B2 (en) 2009-12-15 2018-03-20 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
WO2011073234A3 (en) * 2009-12-15 2012-04-19 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
CN105125508A (en) * 2009-12-15 2015-12-09 阿森迪斯药物生长障碍股份有限公司 Growth hormone composition
AU2010332958B2 (en) * 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
US9511122B2 (en) 2009-12-15 2016-12-06 Ascendis Pharma Growth Disorders Division A/S Dry growth hormone composition transiently linked to a polymer carrier
CN102711733A (en) * 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 Growth hormone composition which is instantly connected with polymer carrier
JP2013513647A (en) * 2009-12-15 2013-04-22 アセンディス ファーマ エー／エス Dry growth hormone composition temporarily linked to a polymer carrier
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2011089216A1 (en) * 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US9533056B2 (en) 2010-01-22 2017-01-03 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US20120035320A1 (en) * 2010-04-03 2012-02-09 University Of Iowa Research Foundation Polyacridine nucleic acid delivery peptide complexes
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9783592B2 (en) 2010-05-13 2017-10-10 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
US9458220B2 (en) 2010-06-16 2016-10-04 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
US10233225B2 (en) 2010-06-16 2019-03-19 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
RU2580317C2 (en) * 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Peptide pro-drugs of amide glucagon superfamily
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CN103179979A (en) * 2010-06-24 2013-06-26 印第安纳大学研究及科技有限公司 Amide based glucagon superfamily peptide prodrugs
WO2011163012A3 (en) * 2010-06-24 2013-07-11 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
AU2011303823B2 (en) * 2010-09-17 2014-07-17 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an exendin linker conjugate
CN103237561B (en) * 2010-09-17 2015-12-02 赛诺菲-安万特德国有限公司 Comprise the prodrug of Exendin junctional complex conjugate
CN103237561A (en) * 2010-09-17 2013-08-07 赛诺菲-安万特德国有限公司 Prodrugs comprising an exendin linker conjugate
JP2013538224A (en) * 2010-09-17 2013-10-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Prodrugs containing exendin linker conjugates
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9133276B2 (en) 2010-09-17 2015-09-15 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an exendin linker conjugate
WO2012035139A1 (en) 2010-09-17 2012-03-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an exendin linker conjugate
RU2593774C2 (en) * 2010-09-17 2016-08-10 Санофи-Авентис Дойчланд Гмбх Prodrugs containing exendin conjugate-linker
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US10174093B2 (en) 2011-06-22 2019-01-08 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9758562B2 (en) 2011-06-22 2017-09-12 Indiana University and Technology Corporation Glucagon/GLP-1 receptor co-agonists
US10730923B2 (en) 2011-06-22 2020-08-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9353172B2 (en) 2011-07-18 2016-05-31 Arts Biologics A/S Long acting biologically active luteinizing hormone (LH) compound
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
WO2013024048A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
EP3643306A2 (en) 2011-08-12 2020-04-29 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
WO2013024049A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Protein carrier-linked prodrugs
WO2013024053A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
US20140323402A1 (en) * 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
WO2013053856A1 (en) 2011-10-12 2013-04-18 Ascendis Pharma A/S Prevention and treatment of ocular conditions
EP2768856A4 (en) * 2011-10-18 2015-05-27 Prolynx Llc Peg conjugates of exenatide
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
US20150087688A1 (en) * 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
WO2013160340A1 (en) 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
AU2013254756B2 (en) * 2012-04-25 2017-03-30 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
WO2013167750A2 (en) 2012-05-11 2013-11-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
US9593156B2 (en) 2012-09-26 2017-03-14 Indiana University Research And Technology Corporation Insulin analog dimers
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
RU2673881C2 (en) * 2012-10-11 2018-12-03 Асцендис Фарма Офтальмолоджи Дивижн А/С Vegf neutralising prodrugs for the treatment of ocular conditions
RU2682676C2 (en) * 2012-10-11 2019-03-20 Асцендис Фарма Ас Diagnosis, prevention and treatment of joint diseases
US10980860B2 (en) 2012-10-11 2021-04-20 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
WO2014056923A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma Ophthalmology Division A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
KR20150065891A (en) * 2012-10-11 2015-06-15 아센디스 파마 옵탈몰로지 디비젼 에이/에스 Vegf neutralizing prodrugs for the treatment of ocular conditions
US9855340B2 (en) 2012-10-11 2018-01-02 Ascendis Pharma A/S Hydrogel prodrugs
WO2014056915A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
US10519226B2 (en) 2012-10-11 2019-12-31 Ascendis Pharma Opthalmology Division A/S VEGF neutralizing prodrugs for the treatment of ocular conditions
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
KR102235868B1 (en) * 2012-10-11 2021-04-07 아센디스 파마 옵탈몰로지 디비젼 에이/에스 Vegf neutralizing prodrugs for the treatment of ocular conditions
WO2014080730A1 (en) 2012-11-22 2014-05-30 株式会社糖鎖工学研究所 Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof
US9708413B2 (en) 2012-11-22 2017-07-18 Glytech, Inc. Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof
KR102227918B1 (en) * 2012-11-22 2021-03-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof
KR20150102003A (en) * 2012-11-22 2015-09-04 가부시키가이샤 도우사 고가쿠 겐큐쇼 Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof
US10202469B2 (en) 2012-11-30 2019-02-12 Glytech, Inc. Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same
WO2014084110A1 (en) 2012-11-30 2014-06-05 株式会社糖鎖工学研究所 Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same
US9745360B2 (en) 2012-12-21 2017-08-29 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US10253079B2 (en) 2012-12-21 2019-04-09 Sanofi Functionalized Exendin-4 derivatives
US10696726B2 (en) 2013-03-14 2020-06-30 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US11116849B2 (en) 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
WO2014173759A1 (en) 2013-04-22 2014-10-30 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
AU2014333954C1 (en) * 2013-10-08 2020-08-27 Ascendis Pharma A/S Protecting group comprising a purification tag
WO2015052154A1 (en) * 2013-10-08 2015-04-16 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-linked il-1ra prodrug
US10040850B2 (en) 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
AU2014333954B2 (en) * 2013-10-08 2020-03-05 Ascendis Pharma A/S Protecting group comprising a purification tag
WO2015067791A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
US10385107B2 (en) 2014-09-24 2019-08-20 Indiana Univeresity Researc and Technology Corporation Lipidated amide-based insulin prodrugs
US12076366B2 (en) 2014-10-22 2024-09-03 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US12133883B2 (en) 2014-11-18 2024-11-05 Ascendis Pharma Endocrinology Division A/S Polymeric hGH prodrugs
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment
RU2728656C2 (en) * 2015-01-09 2020-07-31 Асцендис Фарма Гроус Дизордерс А/С Cnp prodrugs
IL278970B2 (en) * 2015-01-09 2024-03-01 Ascendis Pharma Growth Disorders As Cnp prodrugs
WO2016110577A1 (en) * 2015-01-09 2016-07-14 Ascendis Pharma A/S Cnp prodrugs
IL278970B1 (en) * 2015-01-09 2023-11-01 Ascendis Pharma Growth Disorders As Cnp prodrugs
RU2824988C1 (en) * 2015-01-09 2024-08-19 Асцендис Фарма Гроус Дизордерс А/С Cnp prodrugs
WO2016196124A2 (en) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Prodrugs comprising a pyroglutamate linker
US11298427B2 (en) 2015-05-29 2022-04-12 Ascendis Pharma A/S Prodrugs comprising a pyroglutamate linker
WO2016193371A1 (en) 2015-06-05 2016-12-08 Sanofi Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate
RU2719482C2 (en) * 2015-06-05 2020-04-17 Санофи Prodrugs containing hyaluronic acid conjugate, linker and double agonist glp-1/glucagon
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
US20180289822A1 (en) * 2015-06-05 2018-10-11 Sanofi Prodrugs comprising an glp-1/glucagon dual agonist linker hyaluronic acid conjugate
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
US11179467B2 (en) 2015-09-25 2021-11-23 Brightgene Bio-Medical Technology Co., Ltd. Exenatide modifier and use thereof
AU2017205693B2 (en) * 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
US11154593B2 (en) 2016-01-08 2021-10-26 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
WO2017118704A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
US12083182B2 (en) 2016-01-08 2024-09-10 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
WO2017118693A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
WO2017118698A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
WO2017118703A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
US11311604B2 (en) 2016-01-08 2022-04-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
EP4162955A1 (en) * 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
AU2022221482B2 (en) * 2016-01-08 2024-02-22 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
KR20180100625A (en) * 2016-01-08 2018-09-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 Controlled-release CNP agonists with low NPR-C binding
US11389510B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
KR102373744B1 (en) 2016-01-08 2022-03-15 아센디스 파마 그로우쓰 디스오더스 에이/에스 Controlled release CNP agonists with low NPR-C binding
AU2017205694B2 (en) * 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
AU2022202280B2 (en) * 2016-01-08 2023-11-02 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
US11413351B2 (en) 2016-01-08 2022-08-16 Ascendis Pharma Growth Disorders A/S CNP prodrugs with carrier attachment at the ring moiety
IL259829B (en) * 2016-01-08 2022-11-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
US11224661B2 (en) 2016-01-08 2022-01-18 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
IL259829B2 (en) * 2016-01-08 2023-03-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
IL260756B1 (en) * 2016-03-01 2023-05-01 Ascendis Pharma Bone Diseases As Pth prodrugs
AU2022256158B2 (en) * 2016-03-01 2023-09-28 Ascendis Pharma Bone Diseases A/S PTH prodrugs
AU2017227962B2 (en) * 2016-03-01 2020-11-12 Ascendis Pharma Bone Diseases A/S PTH prodrugs
AU2022256158A9 (en) * 2016-03-01 2023-09-28 Ascendis Pharma Bone Diseases A/S PTH prodrugs
WO2017148883A1 (en) 2016-03-01 2017-09-08 Ascendis Pharma Bone Diseases A/S Pth prodrugs
KR102331820B1 (en) 2016-03-01 2021-11-29 아센디스 파마 본 디지즈 에이/에스 PTH prodrug
IL260756B2 (en) * 2016-03-01 2023-09-01 Ascendis Pharma Bone Diseases As Pth prodrugs
KR102524255B1 (en) * 2016-03-01 2023-04-20 아센디스 파마 본 디지즈 에이/에스 Pth prodrugs
KR20210147085A (en) * 2016-03-01 2021-12-06 아센디스 파마 본 디지즈 에이/에스 Pth prodrugs
US11793861B2 (en) 2016-03-01 2023-10-24 Ascendis Pharma Bone Diseases A/S PTH prodrugs
AU2017227962C1 (en) * 2016-03-01 2021-05-13 Ascendis Pharma Bone Diseases A/S PTH prodrugs
KR20180118197A (en) * 2016-03-01 2018-10-30 아센디스 파마 본 디지즈 에이/에스 PTH prodrug
WO2017186250A1 (en) 2016-04-29 2017-11-02 Defensin Therapeutics Aps Treatment of liver, biliary tract and pancreatic disorders
AU2017295938C1 (en) * 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
AU2017295938B2 (en) * 2016-07-13 2021-05-20 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
EP4275677A2 (en) 2016-09-29 2023-11-15 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
US11857603B2 (en) 2016-09-29 2024-01-02 Ascendis Pharma Bone Diseases A/S PTH compounds with low peak-to-trough ratios
US11918628B2 (en) 2016-09-29 2024-03-05 Ascendis Pharma Bone Diseases A/S Controlled-release PTH compound
AU2017336250B2 (en) * 2016-09-29 2023-04-20 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
WO2018060312A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
AU2017336250C1 (en) * 2016-09-29 2023-08-03 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
US11590207B2 (en) 2016-09-29 2023-02-28 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release PTH compound
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
WO2018060310A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
WO2018060314A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
US11759504B2 (en) 2016-09-29 2023-09-19 Ascendis Pharma Bone Diseases A/S PTH compounds with low peak-to-trough ratios
IL290054B2 (en) * 2016-09-29 2024-03-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
CN109789221B (en) * 2016-09-29 2022-11-01 阿森迪斯药物骨疾病股份有限公司 Pharmaceutical composition for controlled release of PTH
CN109789221A (en) * 2016-09-29 2019-05-21 阿森迪斯药物骨疾病股份有限公司 Ascending-dose discovery in controlled release PTH compound
IL290054B1 (en) * 2016-09-29 2023-11-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
WO2018060311A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
US11890326B2 (en) 2016-09-29 2024-02-06 Ascendis Pharma Bone Diseases A/S Controlled-release PTH compound
US10792367B2 (en) 2016-12-02 2020-10-06 Sanofi Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
US11141489B2 (en) 2016-12-02 2021-10-12 Sanofi Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
WO2018100174A1 (en) 2016-12-02 2018-06-07 Sanofi Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
WO2018108971A2 (en) 2016-12-13 2018-06-21 Defensin Therapeutics Aps Methods for treating inflammatory conditions of the lungs
US11786599B2 (en) 2017-03-10 2023-10-17 Quiapeg Pharmaceuticals Ab Releasable conjugates
WO2018175788A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US11642415B2 (en) 2017-03-22 2023-05-09 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US10751417B2 (en) 2017-04-20 2020-08-25 Novartis Ag Sustained release delivery systems comprising traceless linkers
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
WO2019076675A1 (en) * 2017-10-06 2019-04-25 Instituto De Medicina Molecular Treatment of obesity-related conditions
WO2019092201A2 (en) 2017-11-10 2019-05-16 Defensin Therapeutics Aps Maturation of mucosal defense and gut/lung function in the preterm infant
WO2019101773A2 (en) 2017-11-24 2019-05-31 Defensin Therapeutics Aps Prevention and treatment of graft-versus-host-disease with defensins
US11370753B2 (en) 2017-12-05 2022-06-28 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11767293B2 (en) 2017-12-05 2023-09-26 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US10874639B2 (en) 2017-12-05 2020-12-29 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US11517558B2 (en) 2017-12-05 2022-12-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US10800738B2 (en) 2017-12-05 2020-10-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
RU2806753C2 (en) * 2018-05-18 2023-11-07 Асцендис Фарма Боун Дизизис А/С Method of treating or control of hypoparathyroidus using parathrooid hormone (pth) conjugate
WO2019219896A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
WO2019229225A1 (en) 2018-05-30 2019-12-05 Sanofi Conjugates comprising an glp-1/glucagon/gip triple receptor agonist, a linker and hyaluronic acid
US11957735B2 (en) 2018-09-12 2024-04-16 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
US11357828B2 (en) 2018-09-12 2022-06-14 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
US20210330807A1 (en) * 2018-09-26 2021-10-28 Ascendis Pharma A/S Novel hydrogel conjugates
WO2020064844A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
WO2020064846A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
US11389541B2 (en) 2018-10-03 2022-07-19 Novartis Ag Sustained delivery of angiopoetin-like 3 polypeptides
WO2020141221A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Conjugates of pattern recognition receptor agonists
WO2020141222A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Sustained local drug levels for innate immune agonists
WO2020141225A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Minimization of systemic inflammation
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
WO2020165081A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
WO2020165087A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11654113B2 (en) 2019-06-04 2023-05-23 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254609A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254606A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
WO2020254611A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254603A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma A/S CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
WO2021136808A1 (en) 2020-01-03 2021-07-08 Ascendis Pharma A/S Conjugates undergoing intramolecular rearrangements
WO2021144249A1 (en) 2020-01-13 2021-07-22 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
US11879001B2 (en) 2020-06-03 2024-01-23 Ascendis Pharma Oncology Division A/S Conjugate comprising an IL-2 moiety
WO2021245130A1 (en) 2020-06-03 2021-12-09 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
WO2022029178A1 (en) 2020-08-05 2022-02-10 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
WO2022043493A1 (en) 2020-08-28 2022-03-03 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
WO2022053696A1 (en) * 2020-09-11 2022-03-17 Compass Pathfinder Limited Novel safrylamine derivatives having prodrug properties
WO2022064035A1 (en) 2020-09-28 2022-03-31 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
WO2022207798A1 (en) 2021-04-01 2022-10-06 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
US11993577B2 (en) 2021-09-01 2024-05-28 Empathbio, Inc. Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
US11845736B2 (en) 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023110727A2 (en) 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
WO2024146920A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma Ophthalmology Division A/S Drug conjugates for the treatment of ocular disorders
WO2024146902A1 (en) 2023-01-05 2024-07-11 Ascendis Pharma A/S Methods of producing hydrogel microspheres
WO2024184351A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
WO2024194300A1 (en) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Also Published As

Publication number Publication date
US8906847B2 (en) 2014-12-09
HRP20191052T1 (en) 2019-11-01
JP2011510954A (en) 2011-04-07
DK2596805T3 (en) 2021-12-13
US20200046725A1 (en) 2020-02-13
CN101980725B (en) 2013-06-12
HK1152240A1 (en) 2012-02-24
US20170100490A1 (en) 2017-04-13
RU2010136023A (en) 2012-03-10
EP2596805B1 (en) 2021-10-27
US20220331334A1 (en) 2022-10-20
US20110053848A1 (en) 2011-03-03
ES2733355T3 (en) 2019-11-28
RU2676324C2 (en) 2018-12-28
PL2237799T3 (en) 2019-09-30
RU2018143571A (en) 2020-06-10
PT2237799T (en) 2019-07-05
LT2237799T (en) 2019-07-25
EP2596805A1 (en) 2013-05-29
HUE044174T2 (en) 2019-10-28
EP2237799B1 (en) 2019-04-10
EP2237799A2 (en) 2010-10-13
IL207150A0 (en) 2010-12-30
CN101980725A (en) 2011-02-23
US20150057221A1 (en) 2015-02-26
EP3981761A2 (en) 2022-04-13
BRPI0906643A2 (en) 2019-09-10
RU2014122036A (en) 2015-12-10
JP2014193908A (en) 2014-10-09
ZA201005413B (en) 2012-04-25
WO2009095479A3 (en) 2009-10-01
AU2009209565B2 (en) 2013-09-19
AU2009209565A1 (en) 2009-08-06
CY1121961T1 (en) 2020-10-14
SI2237799T1 (en) 2019-07-31
CA2712224C (en) 2016-03-08
CA2712224A1 (en) 2009-08-06
DK2237799T3 (en) 2019-06-11
EP3981761A3 (en) 2022-08-24
US20240041897A1 (en) 2024-02-08
JP5588354B2 (en) 2014-09-10
IL207150A (en) 2013-07-31
RS58948B1 (en) 2019-08-30
MX2010008024A (en) 2010-12-21
ES2904673T3 (en) 2022-04-05

Similar Documents

Publication Publication Date Title
US20220331334A1 (en) Prodrug Comprising a Drug-Linker Conjugate
CA2811352C (en) Prodrugs comprising an exendin linker conjugate
EP2459171A1 (en) Long acting insulin composition
SG178193A1 (en) Prodrugs comprising an insulin linker conjugate
RU2798085C2 (en) Prodrug containing a self-cleavable linker
RU2798085C9 (en) Prodrug containing a self-cleavable linker

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980111088.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09706788

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009209565

Country of ref document: AU

Ref document number: 2712224

Country of ref document: CA

Ref document number: 2009706788

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 207150

Country of ref document: IL

Ref document number: MX/A/2010/008024

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 4702/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010544717

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009209565

Country of ref document: AU

Date of ref document: 20090130

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010136023

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12865693

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0906643

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100730